1	Accuracy of rapid point-of-care antigen-based diagnostics for SARS-CoV-2: an updated sys-
2	tematic review and meta-analysis with meta regression analyzing influencing factors
3	
4	Lukas E. Brümmer ¹⁺ , Stephan Katzenschlager ²⁺ , Sean McGrath ³ , Stephani Schmitz ⁴ , Mary Gaeddert ¹ ,
5	Christian Erdmann ⁵ , Marc Bota ⁶ , Maurizio Grilli ⁷ , Jan Larmann ² , Markus A. Weigand ² , Nira R. Pollock ⁸ ,
6	Aurélien Macé ⁹ , Berra Erkosar ⁹ , Sergio Carmona ⁹ , Jilian A. Sacks ⁹ , Stefano Ongarello ⁹ , Claudia M. Den-
7	kinger ^{1, 10}
8	
9	⁺ These authors contributed equally
10	* Corresponding author (<u>Claudia.Denkinger@uni-heidelberg.de)</u>
11	
12	1) Division of Infectious Disease and Tropical Medicine, Center for Infectious Diseases, Heidelberg Uni-
13	versity Hospital, Heidelberg, Germany
14	2) Department of Anesthesiology, Heidelberg University Hospital, Heidelberg, Germany
15	3) Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts,
16	United States of America
17	4) Department of Developmental Biology, Erasmus Medical Center, Rotterdam, Netherlands
18	5) FH Muenster University of Applied Sciences, Muenster, Germany
19	6) Agaplesion Bethesda Hospital, Hamburg, Germany
20	7) Library, University Medical Center Mannheim, Mannheim, Germany
21	8) Department of Laboratory Medicine, Boston Children's Hospital, Boston, Massachusetts, United
22	States of America
23	9) FIND, Geneva, Switzerland
24	10) German Center for Infection Research (DZIF), partner site Heidelberg University Hospital, Heidel-
25	berg, Germany
26	
27	
28	
29	Keywords: SARS-CoV-2; Antigen Test; PCR; meta-analysis; meta-regression

30 Running Title: Accuracy of point-of-care Ag-RDTs for SARS-CoV-2

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 ABSTRACT

32 Background

Comprehensive information about the accuracy of antigen rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2 is essential to guide public health decision makers in choosing the best tests and testing policies. In August 2021, we published a systematic review and meta-analysis about the accuracy of Ag-RDTs. We now update this work and analyze the factors influencing test sensitivity in further detail.

37 Methods and findings

38 We registered the review on PROSPERO (registration number: CRD42020225140). We systemat-39 ically searched multiple databases (PubMed, Web of Science Core Collection, medRvix, bioRvix, and FIND) for publications evaluating the accuracy of Ag-RDTs for SARS-CoV-2 until August 31, 2021. De-40 41 scriptive analyses of all studies were performed, and when more than 4 studies were available, a ran-42 dom-effects meta-analysis was used to estimate pooled sensitivity and specificity with reverse tran-43 scription polymerase chain reaction (RT-PCR) testing as a reference. To evaluate factors influencing 44 test sensitivity, we performed 3 different analyses using multivariate mixed-effects meta-regression 45 models. We included 194 studies with 221,878 Ag-RDTs performed. Overall, the pooled estimates of Ag-RDT sensitivity and specificity were 72.0% (95% confidence interval [CI] 69.8 to 74.2) and 98.9% 46 47 (95% CI 98.6 to 99.1), respectively. When manufacturer instructions were followed, sensitivity in-48 creased to 76.4% (95%CI 73.8 to 78.8). Sensitivity was markedly better on samples with lower RT-PCR 49 cycle threshold (Ct) values (sensitivity of 97.9% [95% Cl 96.9 to 98.9] and 90.6% [95% Cl 88.3 to 93.0] 50 for Ct-values <20 and <25, compared to 54.4% [95% CI 47.3 to 61.5] and 18.7% [95% CI 13.9 to 23.4] 51 for Ct-values \geq 25 and \geq 30) and was estimated to increase by 2.9 percentage points (95% Cl 1.7 to 4.0) 52 for every unit decrease in mean Ct-value when adjusting for testing procedure and patients' symptom 53 status. Concordantly, we found the mean Ct-value to be lower for true positive (22.2 [95% CI 21.5 to 22.8]) compared to false negative (30.4 [95% CI 29.7 to 31.1]) results. Testing in the first week from 54 symptom onset resulted in substantially higher sensitivity (81.9% [95% CI 77.7 to 85.5]) compared to 55 56 testing after 1 week (51.8%, 95% CI 41.5 to 61.9). Similarly, sensitivity was higher in symptomatic

57	(76.2% [95% CI 73.3 to 78.9]) compared to asymptomatic (56.8% [95% CI 50.9 to 62.4]) persons. How-
58	ever, both effects were mainly driven by the Ct-value of the sample. With regards to sample type,
59	highest sensitivity was found for nasopharyngeal (NP) and combined NP/oropharyngeal samples
60	(70.8% [95% CI 68.3 to 73.2]), as well as in anterior nasal/mid-turbinate samples (77.3% [95% CI 73.0
61	to 81.0]).
62	Conclusion
63	Ag-RDTs detect most of the individuals infected with SARS-CoV-2, and almost all when high viral
64	loads are present (>90%). With viral load, as estimated by Ct-value, being the most influential factor
65	on their sensitivity, they are especially useful to detect persons with high viral load who are most likely
66	to transmit the virus. To further quantify the effects of other factors influencing test sensitivity, stand-
67	ardization of clinical accuracy studies and access to patient level Ct-values and duration of symptoms
68	are needed.

69 INTRODUCTION

Antigen rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2 have proven to be a cornerstone in fighting the COVID-19 pandemic, as they provide results quickly and are easy to use [1]. Nevertheless, the Ag-RDTs' performance differs widely between manufacturers, the way they are performed, and the patients in which they are used [2, 3]. Thus, a comprehensive synthesis of evidence on commercially available Ag-RDTs and the factors influencing their accuracy is vital to guide public health decision makers in choosing the right test for their needs [4].

76 We previously conducted a living systematic review (available online at www.diagnosticsglob-77 alhealth.org and updated weekly until August 31, 2021), summarizing the accuracy of commercially 78 available Ag-RDTs reported in scientific literature. In an earlier analysis, including studies up until April 79 30, 2021, the pooled estimates of Ag-RDT sensitivity and specificity were 71.2% (95% confidence inter-80 val (CI) 68.2% to 74.0%) and 98.9% (95% CI 98.6% to 99.1%), respectively, with the SARS-CoV-2 Antigen 81 Test (LumiraDx, UK; henceforth called LumiraDx) being the most sensitive [4]. Since then, many addi-82 tional studies have been published with a substantial increase in studies assessing asymptomatic par-83 ticipants, allowing for further sub-analysis of findings [3]. In prior studies, we and others found Ag-RDT 84 sensitivity to decrease significantly in persons with lower viral load, as estimated by Ct-value, as well 85 as asymptomatic persons or persons with more than 7 days since symptom onset (DOS > 7) [4]. However, studies including symptomatic patients enroll persons typically within days since onset of symp-86 87 toms [5], when viral load is highest [6, 7]. On the contrary, studies including only asymptomatic persons 88 have a higher chance of including persons at a later stage in the disease and thus with lower viral load. Therefore, the decrease in Ag-RDT sensitivity might only be driven by viral load, irrespective of persons' 89 90 symptom status.

91 With the present work, we aim not only to give an updated overview on the accuracy of commer-92 cially available Ag-RDTs, but also to further explore the impact of viral load, the presence of symptoms 93 and testing procedure on the accuracy of Ag-RDTs.

94 METHODS

95 We developed a study protocol following standard guidelines for systematic reviews [8, 9], which 96 is available in the supplements (S1 Text). We also completed the PRISMA checklist (S1 PRISMA Check-97 list), and registered the review on PROSPERO (registration number: CRD42020225140).

98

99 Search strategy

100 We performed a search of the databases PubMed, Web of Science, medRxiv, and bioRxiv. The 101 search terms were developed with an experienced medical librarian (M. Grilli), using combinations of 102 subject headings (when applicable) and text-words for the concepts of the search question. The main 103 search terms were "Severe Acute Respiratory Syndrome Corona-virus 2", "COVID-19", "Betacorona-104 virus", "Coronavirus", and "Point of Care Testing" with no language restrictions. The full list of search 105 terms is available in S2 Text. We also manually searched the website of FIND, the global alliance for 106 diagnostics (https://www.finddx.org/sarscov2-eval-antigen/), for additional relevant studies. We per-107 formed the search bi-weekly through August 31, 2021. The last manual search of the FIND website was 108 performed on September 10, 2021. In addition to conducting the present review, we updated our website www.diagnosticsglobalhealth.org weekly with the latest search results based on the methods 109 110 outlined below.

111

112 Inclusion criteria

We included studies evaluating the accuracy of commercially available Ag-RDTs to establish a diagnosis of SARS-CoV-2 infection at the point-of-care (POC), against reverse transcription polymerase chain reaction (RT-PCR) or cell culture as reference standard. We included all study populations irrespective of age, presence of symptoms or study location. We considered cohort studies, nested cohort studies, case–control or cross-sectional studies, and randomized studies. We included both peer-reviewed publications and preprints.

We excluded studies, in which patients were tested for the purpose of monitoring or ending quar-119 120 antine. Also, publications with a population size smaller than 10 were excluded (although the size 121 threshold of 10 is arbitrary, such small studies are more likely to give unreliable estimates of sensitivity and specificity). Analytical accuracy studies, where tests are performed on spiked samples with a 122 123 known quantity of virus, were also excluded. 124 125 Index tests 126 Ag-RDTs for SARS-CoV-2 aim to detect infection by recognizing viral proteins (typically the SARS-127 CoV-2 nucleoprotein). Most Ag-RDTs dedicated for point-of-care deployment use specific labeled antibodies attached to a nitrocellulose matrix strip (lateral flow assay), to capture and detect the viral 128 129 antigen. Successful binding of the antibodies to the antigen either is detected visually by the appear-130 ance of a line on the matrix strip or through a specific reader instrument for fluorescence detection. Other point-of-care instrument-based tests use chips or cartridges that enable an automated immu-131 132 noassay testing procedure. Ag-RDTs typically provide results within 10 to 30 minutes [10]. 133 134 **Reference standard** Viral culture detects viable virus that is relevant for transmission but is only available in research 135 settings. Since RT-PCR tests are more widely available and SARS-CoV-2 RNA (as reflected by RT-PCR 136 137 cycle threshold [Ct] value) highly correlates with SARS-CoV-2 antigen quantities [11], we considered 138 RT-PCR an acceptable reference standard for the purposes of this systematic review. Where an international standard for the correlation of the viral load to the Ct-values was used, we also report the 139 140 viral load [12]. 141 The study selection, data extraction, assessment of the quality of studies and their independence 142 from manufacturers were performed as per prior description [4]. The data items extracted can be 143

144 found in the Supplement (S1 Table).

145

146 Statistical analysis and data synthesis

We extracted raw data from the studies and recalculated performance estimates where possible 147 based on the extracted data. Also, some primary studies reported the median Ct-value along with the 148 149 first and third interguartile range (IQR) and/or minimum and maximum values rather than the sample 150 mean and standard deviation. To incorporate these studies in our analyses, we applied the Quantile 151 Estimation approach [13] to estimate the mean and standard deviation of the Ct-values. In an effort to 152 use as much of the heterogeneous data as possible, the cutoffs for the Ct value groups were relaxed 153 by 2–3 points within each range. The <20 group included values reported up to \leq 20, the <25 group 154 included values reported as ≤ 24 or ≤ 25 or 20-25, and the ≤ 30 group included values from ≤ 29 to ≤ 33 155 and 25–30. The \geq 25 group included values reported as \geq 25 or 25 to 30, and the \geq 30 group included 156 values from \geq 30 to \geq 35. For the same reason, when categorizing by age, the age group <18 years (chil-157 dren) included samples from persons whose age was reported as <16 or <18 years, whereas the age 158 group \geq 18 years (adults) included samples from persons whose age was reported as \geq 16 or \geq 18 years. 159 Also, for the symptom duration groups, the ≤ 7 days group included $\leq 4, \leq 5, \leq 6, 6$ to 7, ≤ 7 and ≤ 9 days, 160 and the >7 days group >5, 6 to 10, 6-21, >7 and 8 to 14 days. The raw data can be found in the supple-161 ments (S2 Table) and with more details online (https://doi.org/10.11588/data/T3MIB0). We prepared forest plots for the sensitivity and specificity of each test and visually evaluated the heterogeneity 162 163 between studies.

164 If 4 or more datasets were available with at least 20 RT-PCR-positive samples per dataset for a 165 predefined analysis, a meta-analysis was performed. We report pooled estimates of sensitivity and 166 specificity for SARS-CoV-2 detection along with 95% confidence intervals (CIs) using a bivariate model 167 (implemented with the "reitsma" command from the R package "mada," version 0.5.10). In subgroup 168 analyses (below), where papers presented data only on sensitivity, a univariate random effects inverse 169 variance meta-analysis was performed (using the "metagen" command from the R package "meta", 170 version 5.1-1, and the "rma" command from the R package "metafor", version 3.0-2). When there were

171 fewer than 4 studies for an index test, only a descriptive analysis was performed, and accuracy ranges172 are reported.

We predefined subgroups for meta-analysis based on the following characteristics: Ct value 173 174 range, testing procedure in accordance with manufacturer's instructions as detailed in the instructions 175 for use (IFU) (henceforth called IFU-conforming) versus not IFU-conforming, age (<18 versus \geq 18 years), sample type, presence or absence of symptoms, symptom duration (<7 days versus \geq 7 days), 176 177 viral load, and type of RT-PCR assay used. We also provide mean Ct-value across true positive and false 178 negative test results. For categorization by sample type, we assessed (1) nasopharyngeal (NP) alone or 179 combined with other (e.g., oropharyngeal [OP]), (2) OP alone, (3) anterior nasal (AN) or mid-turbinate 180 (MT), (4) a combination of bronchoalveolar lavage and throat wash (BAL/TW), or (5) saliva.

181 We applied multivariate linear mixed-effect meta-regression models to explore factors that affect 182 diagnostic test sensitivity. Based on our previous analysis [4], we a priori defined an individual's time 183 since infection and sample type and condition as underlying factors, influencing test sensitivity through 184 an individual's symptom status (symptomatic vs. asymptomatic), the samples' viral load (estimated by 185 the mean Ct-value as presented in the study for the sub cohort of interest) and the testing procedure (IFU- vs. not IFU-conforming). We performed 3 different analyses, each of which obtained unadjusted 186 187 and adjusted estimates (i.e., an estimate of the association between a factor and test sensitivity, hold-188 ing the other covariates in the model constant) of the effect of factors on test sensitivity.

189 In the first analysis, we estimated the direct effect of symptom status, viral load and testing pro-190 cedure on test sensitivity. For the second and third analysis, we restricted the meta-regression models 191 to data sets of symptomatic persons due to a lack of data. Specifically, the second analysis assessed 192 the effect of time since infection (estimated as the sample mean of symptom duration), viral load, and 193 testing procedure on test sensitivity. The third analysis also assessed the effect of time since infection, 194 viral load, and testing procedure on test sensitivity, but depicted the time since infection as a binary 195 covariate of the symptom duration subgroup (≤ 7 vs >7 days). Further details on the implementation of 196 the meta-regression models and the underlying casual diagrams are available in the Supplement (S3

197 Text, S3a to S3c). Data sets with less than 5 RT-PCR positives were excluded. We considered an effect 198 to be statistically significant when the regression coefficient's 95% confidence interval did not include 199 0. The analyses were performed using the "metafor" R package, version 3.0-2 [14]. 200 As recommended to investigate publication bias for diagnostic test accuracy meta-analyses, we 201 performed the Deeks test for funnel-plot asymmetry [15] (using the "midas" command in Stata, ver-202 sion 15); a p-value < 0.10 for the slope coefficient indicates significant asymmetry. 203 204 Sensitivity analysis 205 3 sensitivity analyses were performed: estimation of sensitivity and specificity excluding case-206 control studies, estimation of sensitivity and specificity excluding not peer-reviewed studies, and esti-207 mation of sensitivity and specificity excluding studies that were potentially influenced through test 208 manufacturers. We compared the results of each sensitivity analysis against the overall results to as-209 sess the potential bias introduced by case-control, not peer-reviewed, and manufacturer-influenced 210 studies. 211 RESULTS 212 213 SUMMARY OF STUDIES 214 The systematic search resulted in 31,254 articles. After removing duplicates, 11,462 articles were 215 screened and 433 papers were considered eligible for full-text review. Of these, 259 were excluded 216 because they did not present primary data or the Ag-RDT was not commercially available, leaving 174 217 studies to be included in the systematic review [16-189]. A list of the studies excluded and their reason 218 for exclusion can be found in the Supplement (S4 Text). Further 20 studies were included from the FIND website [190-209] (Fig 1). 219



221

222 Fig 1: PRISMA flow diagram

Based on Page, M.J., et al. [210]. Abbreviations: Ag-RDT = antigen rapid diagnostic tests; IFU = instructions for use.

225

226 At the end of the data extraction process, 21 studies were still in preprint form [16, 17, 21, 47, 50, 227 55, 58, 65, 69, 74, 84, 100, 116, 121, 129, 160, 167, 168, 173, 174, 186]. All studies were written in 228 English, except for 3 in Spanish [53, 62, 134], 1 in Turkish [95], and 1 in French [153]. Out of the 196 229 studies, 26 conducted a case-control study [21, 32, 34, 66, 67, 72, 81, 84, 88-90, 93, 94, 96, 103, 108, 230 135, 140, 144, 145, 151, 156, 166, 168, 182, 184], while the remaining 168 were cross-sectional or 231 cohort studies. The reference method was RT-PCR in all except 1 study, which used viral culture [135]. 232 The 194 studies were divided into 333 data sets. Across these, 76 different Ag-RDTs were evalu-233 ated (75 lateral flow assays, of which 63 are interpreted visually and 12 required an automated, pro-234 prietary reader; 1 assay is an automated immunoassay). The most common reasons for testing were

the occurrence of symptoms (98 data sets; 29.4% of data sets) and screening of asymptomatic persons
with (3; 0.9%) or without (22; 6.6%) close contact to a SARS-CoV-2 confirmed case. In 142 (42.6%) of
the data sets, individuals were tested due to more than 1 of the reasons mentioned and for 68 (20.4%)
the reason for testing was unclear.

239 In total, 221,878 Ag-RDTs were performed, with a mean number of samples per study of 666 240 (Range 15 to 22,994). The age of the individuals tested was specified for only 90,986 samples, of which 241 84,124 (92.5%) were from adults (age group \geq 18) and 6,862 (7.5%) from children (age group <18). 242 Symptomatic persons comprised 74,118 (33.4%) samples, while 97,982 (44.2%) samples originated from asymptomatic persons, and for 49,778 (22.4%) samples the participant's symptom status was not 243 244 stated by the authors. The most common sample type evaluated was NP and mixed NP/OP (117,187 245 samples, 52.8%), followed by AN/MT (86,354 samples, 38.9%). There was substantially less testing 246 done on the other sample types, with 3,586 (1.6%) tests done from OP samples, 1,256 (0.6%) from 247 saliva, 219 (0.1%) from BAL/TW and for 13,276 (6.0%) tests the type of sample was not specified in the 248 respective studies.

A summary of the tests evaluated in clinical accuracy studies, including study author, sample size, sample type, sample condition, IFU conformity, and symptom status can be found in Supplement (S2 Table). The Standard Q test (SD Biosensor, South Korea; distributed in Europe by Roche, Germany; henceforth called Standard Q) was the most frequently used with 57 (17.1%) data sets and 36,246 (16.3%) tests, while the Panbio test (Abbott Rapid Diagnostics, Germany; henceforth called Panbio) was assessed in 55 (16.5%) data sets with 38,620 (17.4%) tests performed. Detailed results for each clinical accuracy study are available in the Supplement (S1 Fig).

256

257 METHODOLOGICAL QUALITY OF STUDIES

The findings on study quality using the QUADAS 2 tool are presented in Fig 2a and b. In 294 (88.3%) data sets a relevant study population was assessed. However, for only 68 (20.4%) of the data sets the selection of study participants was considered representative of the setting and population

261 chosen (i.e., they avoided inappropriate exclusions or a case-control design and enrollment occurred

262 consecutive or randomly).

263



264

Fig 2a&b: (a)Methodological quality of the clinical accuracy studies (risk of bias) (b) Methodological quality of the clinical accuracy studies (applicability)

267

268 The conduct and interpretation of the index tests was considered to have low risk of bias in 176 269 (52.9%) data sets (e.g., through appropriate blinding of persons interpreting the visual read-out). How-270 ever, for 155 (46.5%) data sets sufficient information to clearly judge the risk of bias was not provided. 271 In only 151 (45.3%) data sets the Ag-RDTs were performed according to IFU, while 138 (41.4%) were not IFU-conforming, potentially impacting the diagnostic accuracy; for 44 (13.2%) data sets the IFU 272 273 status was unclear. The most common deviations from the IFU were (1) use of samples that were pre-274 diluted in transport media not recommended by the manufacturer (113 data sets; 12 unclear), (2) use 275 of banked samples (103 data sets; 12 unclear), and (3) a sample type that was not recommended for 276 Ag-RDTs (8 data sets; 11 unclear).

In 126 (37.8%) data sets the reference standard was performed before the Ag-RDT, or the operator conducting the reference standard was blinded to the Ag-RDT results, resulting in a low risk of bias.

In almost all other data sets (206; 61.9%) this risk could not be assessed, due to missing information and for 1 data set (0.3%) intermediate concern was raised. The applicability of the reference test was judged to be of low concern for all data sets, as viral culture or RT-PCR are considered to adequately define the target condition for the purpose of this study.

In 327 (98.2%) data sets, the sample for the index test and reference test were obtained at the same time, while this was unclear in 6 (1.8%). In 226 (67.9%) data sets, the same RT-PCR assay was used as the reference of all included samples, while in 85 (25.5%) data sets multiple RT-PCR assays were used as the reference. For 22 (6.6%) data sets, the RT-PCR used as reference standard was unclear. Furthermore, for 19 (5.7%) data sets, there was a concern that not all selected study participants were included in the analysis.

Finally, 45 (23.3%) of the studies received financial support from the Ag-RDT manufacturer. In 13 of these as well as in 2 others (in total 7.7% of all studies), employment of the authors by the manufacturer of the Ag-RDT studied was indicated. The respective studies are listed in the Supplement (S5 Text). Overall, a competing interest was found in 47 (24.2%) of the studies. Detailed assessment of each QUADAS domain can be found in the Supplement (S2 Fig).

294

295 DETECTION OF SARS-COV-2 INFECTION

Overall, 38 data sets were excluded from the meta-analysis, as they included fewer than 20 RT-PCR positive samples. An additional 28 data sets were missing either sensitivity or specificity and were only considered for univariate analyses. The remaining 267 data sets, evaluating 198,584 tests, provided sufficient data for bivariate analysis. The results are presented in Fig 3a-e. Detailed results for the subgroup analysis are available in the Supplement (S3 Fig, S4 Fig, S5 Fig, S6 Fig and S7 Fig).

Including any test and type of sample, the pooled estimates of sensitivity and specificity were
 72.0% (95%CI 69.8 to 74.2) and 98.9% (95%CI 98.6 to 99.1), respectively. If testing was performed
 according to IFU, sensitivity increased to 76.4% (95%CI 73.8 to 78.8) compared to not IFU-conforming

304	testing with a sensitivity of 66.7% (95%CI 62.6 to 70.6). Pooled specificity was similar in both groups:
305	99.1% (95% CI 98.8-99.3) and 98.4% (95% CI 97.8 to 98.8), respectively (Fig 3a).

306

307 Subgroup analysis by Ct-value

In samples with Ct-values <20 a very high estimate of sensitivity was found (97.9% [95% CI 96.9 to 98.9]). The pooled sensitivity for Ct-values <25 was markedly better at 90.6% (95% CI 88.3 to 93.0) compared to the group with Ct \ge 25 at 54.4% (95% CI 47.3 to 61.5). A similar pattern was observed when the Ct-values were analyzed using cut-offs <30 or \ge 30, resulting in an estimated sensitivity of 76.8% (95% CI 73.1 to 80.4) and 18.7% (95% CI 13.9 to 23.4), respectively (Fig 3b).

When pooling Ct-value estimates for true positive (TP) Ag-RDT results (TP; 5,083 samples; 69 data sets) and false negative (FN) (2,408 samples; 78 data sets) Ag-RDT results, the mean Ct-values were 22.2 (95% CI 21.5 to 22.8) and 30.4 (95% CI 29.7 to 31.1), respectively (S8 Fig). Across both TP and FN samples, mean Ct-value was 26.3 (95% CI 25.5 to 27.1). This demonstrates that RT-PCR positive samples missed by Ag-RDT have a substantially lower viral load (higher Ct-value) compared to those that were detected. Individual forest plots for each data set with mean Ct-values are presented in the Supplement (S9 Fig).

320

321 Subgroup analysis by sample type

322 Most data sets evaluated NP or combined NP/OP swabs (197 data sets and 104,341 samples) as 323 the sample type for the Ag-RDT. NP or combined NP/OP swabs achieved a pooled sensitivity of 70.8% 324 (95% CI 68.3 to 73.2) and specificity of 98.8% (95% CI 98.6 to 99.1). Data sets that used AN/MT swabs 325 for Ag-RDTs (52 data sets and 84,020 samples) showed a summary estimate for sensitivity of 77.3% 326 (95% CI 73.0 to 81.0) and specificity of 99.1% (95% CI 98.6 to 99.4). However, 2 studies that reported 327 direct head-to-head comparison of NP and AN/MT samples from the same participants using the same 328 Ag-RDT (Standard Q) reported equivalent performance [112, 113]. In contrast, saliva swabs (4 data 329 sets, 1,216 samples) showed the lowest pooled sensitivity with only 50.1% (95% CI 7.7 to 92.3) (Fig 3c).

In 3 of the data sets utilizing a saliva sample, saliva was collected as whole mouth fluid [20, 88, 150].

The fourth used a cheek swab for sample collection [51].

Due to only 3 data sets with 3586 samples, we were not able to estimate pooed sensitivity and specificity for OP samples. Median sensitivity and specificity were 59.4% (range 50.0% to 81.0%) and 99.1% (range 99.0% to 100.0%), respectively. We were also not able to perform a subgroup metaanalysis for BAL/TW due to insufficient data, with only 1 study with 73 samples evaluating the Biocredit Covid-19 Antigen rapid test kit (RapiGEN, South Korea; henceforth called Rapigen), Panbio and Standard Q available and sensitivity ranging between 33.3% and 88.1% [151]. However, the use of BAL/TW sampling would be considered not IFU-conforming.

339

340 Subgroup analysis in symptomatic and asymptomatic participants

Within the data sets possible to meta-analyze, 55,186 (43.2%) samples were from symptomatic and 72,457 (56.8%) from asymptomatic persons. The pooled sensitivity for symptomatic persons was markedly higher compared to asymptomatic persons with 76.2% (95% CI 73.3 to 78.9) vs. 56.8% (95% CI 50.9 to 62.4). Specificity was above 98.6% for both groups (Fig 3d).

345

346 Subgroup analysis comparing symptom duration

Data were analyzed for 9,470 persons from 26 data sets with symptoms less than 7 days, while for persons with symptoms \geq 7 days fewer data were available (620 persons, 13 data sets). The pooled sensitivity estimate for individuals with symptoms <7 days was 81.9% (95% CI 77.7 to 85.5), which is markedly higher than the 51.8% (95% CI 41.5 to 61.9) sensitivity for individuals tested \geq 7 days from onset of symptoms (Fig 3d).

352

353 Subgroup analysis by age

For adults (age group ≥18), it was possible to pool estimates across 62,433 samples, whereas the
 pediatric group (age group <18) included 5,137 samples. There was only a small difference with

overlapping confidence intervals in sensitivity with 74.8% (95% Cl 71.5 to 77.8) and 69.8% (95% Cl 61.0
to 77.3) for the adult and pediatric group, respectively. For those data sets that reported a median Ctvalue per age group, the Ct-value was slightly lower in the adult (median 22.6; Q1 = 20.5; Q3 = 24.6;
48 data sets) compared to the pediatric group (median 23.2; Q1 = 20.3; Q3 = 25.2; 3 data sets). Specificity was similar in both groups with over 99% (Fig 3e).

361



363 Fig 3a-e: Pooled sensitivity and specificity by IFU conformity, Ct-value*, sample type, symptom

364 status, duration of symptoms and age

- *Low Ct-values are the RT-PCR semi-quantitative correlate for a high virus concentration. Abbre viations: N = number of, CI = confidence interval, IFU = instructions for use, NP = nasopharyngeal, AN
 = anterior nasal, MT = mid turbinate, *only sensitivity calculated
- 368

369 META REGRESSION

The first analysis, assessing all variables that could influence sensitivity (symptom status, testing procedure [IFU-conforming vs. not IFU-conforming], and mean Ct-value), included 65 data sets of symptomatic and 18 of asymptomatic persons. The second and third analysis assessed only symptomatic persons with 28 and 50 data sets, respectively. The full list of data sets for each analysis and detailed results are available in the Supplement (S3 Text).

375 In the first analysis, we found viral load (as estimated by Ct-value) to be the driving factor of 376 sensitivity. Sensitivity was estimated to increase by 2.9 percentage points (95% Cl 1.7 to 4.0) for every 377 unit the mean Ct-value decreased (Fig 4, Supplement Text S3d), after adjusting for symptom status and 378 testing procedure. In addition, sensitivity was estimated to be 20.0 percentage points (95% CI 13.7 to 379 26.3) higher for samples from symptomatic compared to asymptomatic participants. However, when 380 controlling for testing procedure and mean Ct-value, this difference declined to only 11.1 percentage 381 points (95% CI 4.8 to 17.4). The difference between IFU-conforming vs. not IFU-conforming testing 382 procedure was not significant (5.2 percentage points [95% CI -2.6 to 13.0] higher for IFU-conforming) 383 after controlling for symptom status and mean Ct-value.



385

386 Fig 4: Pooled estimate of sensitivity across mean Ct-values holding symptom status and IFUstatus constant at their respective means 387 388 Dotted lines are the corresponding 95% confidence intervals. The size of each point is a function

389 of the weight of the data set in the model, where larger data sets have larger points. Abbreviations: Ct 390 = cycle threshold

391

392 When assessing only symptomatic participants, test sensitivity was estimated to decrease by 3.2 393 percentage points (95% CI -1.5 to 7.9) for every 1 day increase in average duration of symptoms (mean 394 duration of symptoms ranged from 2.75 to 6.47 days). However, with the confidence interval including the value zero, this effect was not statistically significant. When controlling for mean Ct-value and test-395 396 ing procedure, the estimated effect of the average duration of symptoms was close to 0 (0.7 percent-397 age points [95% CI -5.0 to 6.4], Supplement Text S3e).

398 Concordantly, for samples collected after 7 days of symptom onset sensitivity was estimated to 399 be 22.9 percentage points [95%Cl 10.3 to 35.4] lower compared to those collected within 7 days. When 400 controlling for mean Ct-value and testing procedure, the model still showed a decrease in sensitivity

- 401 for samples collected after 7 days of symptom onset, but again closer to zero and no longer statistically
- 402 significant (-13.8 percentage points [95% CI -27.7 to 0.1], Supplement Text S3f).

403

- 404 ANALYSIS OF INDIVIDUAL TESTS
- 405 Based on 179 data sets with 143,803 tests performed, we were able to perform bivariate meta-
- 406 analysis of the sensitivity and specificity for 12 different Ag-RDTs (Fig 5). Across these, pooled estimates
- 407 of sensitivity and specificity on all samples were 71.6% (95%CI 69.0 to 74.1) and 99.0% (95% CI 98.8 to
- 408 99.2), which were very similar to the overall pooled estimate across all meta-analyzed data sets (72.0%
- 409 and 98.9%, above).

410

Test assessed	N datasets	Total Sample Size	Pooled Sensitivity (95% CI)	Pooled Specificity (95% CI)		
BD Veritor	7	5721	71.2% (56.8-82.3)	99.2% (98.6-99.6)	II	•
BinaxNow	11	31104	68.5% (54.3-79.9)	99.4% (98.2-99.8)	II	
CLINITEST	4	1006	75.2% (49.8-90.3)	98.7% (97.2-99.4)	• • • •	×
Coris	7	1882	48.4% (36.1-61)	99.1% (98.1-99.6)	⊢–1	
Innova	4	7218	72.2% (47.1-88.4)	99.3% (94.1-99.9)	I	H
LumiraDx	11	4772	82.7% (73.2-89.4)	96.9% (94.4-98.3)	I-=1	H
Panbio	48	32370	71.9% (66.8-76.4)	99.5% (99.2-99.7)		•
Rapigen	6	2116	62% (46.7-75.2)	98.5% (94-99.6)	II	H
Sofia	11	9739	76.4% (70.9-81.2)	99% (98.3-99.4)	H=0	•
Standard F	11	9259	66.4% (57.3-74.4)	97.9% (96.9-98.5)	I-=-(
Standard Q	51	35664	70.9% (65.9–75.5)	98.8% (98.2-99.2)	(=)	
Standard Q nasal	8	2952	81.4% (73.8-87.2)	99.1% (98.4-99.5)	()	•
				Г 0	0.25 0.5 0.75 1 0.5 Sensitivity 5	0.75 1 Specificity

411

412 Fig 5: Bivariate analysis of 12 Ag-RDTs

Pooled sensitivity and specificity were calculated based on reported sample size, true positives, true negatives, false positives, and false negatives. Abbreviations: N = number of, CI = confidence interval

416

The highest pooled sensitivity was found for the SARS-CoV-2 Antigen Test (LumiraDx, United Kingdom; henceforth called LumiraDx) and the Standard Q nasal test (SD Biosensor, South Korea;

distributed in Europe by Roche, Germany; henceforth called Standard Q nasal) with 82.7% (95% CI 73.2 419 420 to 89.4) and 81.4% (95% CI 73.8 to 87.2), respectively. However, all tests except the COVID-19 Ag Respi-421 Strip (Coris BioConcept, Belgium; henceforth called Coris; sensitivity 48.4% (95% Cl 36.1 to 61.0) had 422 confidence intervals that were overlapping. The pooled specificity was above 98% for all of the tests, 423 except for the Standard F test (SD Biosensor, South Korea; henceforth called Standard F) and LumiraDx 424 with specificities of 97.9% (95% CI 96.9 to 98.5) and 96.9% (95% CI 94.4 to 98.3), respectively. Hierar-425 chical summary receiver-operating characteristic for LumiraDx and Standard Q nasal are available in 426 the Supplement (S10 Fig).

427 For 2 Ag-RDTs, we were only able to perform a univariate analysis, due to insufficient data. Sen-428 sitivities for the COVID-19 Rapid Antigen Test Cassette (SureScreen, United Kingdom; henceforth called 429 SureScreen V) and the Nadal COVID-19 Ag Test (Nal von Minden, Germany; henceforth called Nadal) 430 were similar with 57.7% (95% CI 40.9 to 74.4) and 56.6% (95% CI 26.9 to 86.3), respectively (Fig S11). 431 Specificity was only possible to calculate for the Nadal, which was lowest throughout the per test anal-432 ysis with 91.1% (95% CI 80.2 to 100). For the remaining 62 Ag-RDTs, there were insufficient numbers 433 of data sets for a uni-or bivariate meta-analysis, but performance estimates for each of these tests are 434 descriptively compared in the Supplement (S3 Table).

435 For Panbio and Standard Q, it was also possible to pool sensitivity per Ct-value subgroup for each 436 individual test. Panbio and Standard Q reached sensitivities of 97.2% (95% CI 95.3 to 99.2) and 98.1% 437 (95% CI 96.3 to 99.9) for Ct-value <20, 89.8% (95% CI 85.4 to 94.3) and 92.6% (95% CI 88.5 to 96.7) for 438 Ct-value <25 and 73.7% (95% CI 66.0 to 81.3) and 75.7% (95% CI 67.9 to 83.4) for Ct-value <30, respec-439 tively. For Ct-value ≥20 sensitivities for Panbio and Standard Q were 89.2% (95% Cl 82.1 to 96.3) and 440 89.0% (95% CI 81.0 to 96.9), 51.3% (95% CI 32.9 to 69.7) and 57.0% (95% CI 36.9 to 77.0) for Ct-value 441 ≥25, and 22.8% (95% CI 11.3 to 34.3) and 23.7% (95% CI 13.6 to 33.8) for Ct-value ≥30, respectively (S4 Fig A-F). For BinaxNow (Abbott Rapid Diagnostics, Germany), LumiraDx, SD Biosensor, Standard F, Coris 442 443 and INNOVA SARS-CoV-2 Antigen Rapid Qualitative Test (Innova Medical Group, USA; henceforth 444 called Innova) sufficient data to pool sensitivity was only available for certain Ct-values, which are

available in the Supplement (S4 Fig A-F) as well. In addition, for 8 tests it was possible to calculate
pooled sensitivity and specificity estimates only including data sets that conformed to the IFU. These
are also listed in the Supplement (S4 Table).

448 In total, 31 studies accounting for 106 data sets conducted head-to-head clinical accuracy evalu-449 ations of different tests using the same sample(s) from the same participant. These data sets are out-450 lined in the Supplement (S2 Table). 9 studies performed their head-to-head evaluation as per IFU and 451 on symptomatic individuals. Across 4 studies, the Standard Q nasal (sensitivity 80.5% to 91.2%) and 452 the Standard Q (sensitivity 73.2% to 91.2%) showed a similar range of sensitivity [112, 126, 211]. 1 453 study reported a sensitivity of 60.4% (95% CI 54.9 to 65.6) for the Standard Q and 56.8% (95% CI 51.3 454 to 62.2) for the Panbio in a mixed study population of symptomatic, asymptomatic and high-risk con-455 tact persons [186]. Another study described a sensitivity of 56.4% (95% CI 44.7 to 67.6) for the Rapigen 456 and 52.6% (95% CI 40.9 to 64) for the SGTi-flex COVID-19 Ag (Sugentech, South Korea) [160]. 1 study 457 included only very few samples and using a not IFU-conforming sample type (BAL), limiting the ability 458 to draw conclusions from the results [151].

459

460 SENSITIVITY ANALYSIS

We performed 3 sensitivity analyses including 213 data sets for non-case-control studies, 216 461 462 data sets including only peer reviewed studies and 190 data sets including only data sets without any 463 manufacturer influence. When excluding case-control studies, the sensitivity and specificity remained 464 at 71.9% (95% CI 69.4 to 74.2) and 99.0% (95% CI 98.8 to 99.2), respectively. Similar, when assessing 465 only peer reviewed studies sensitivity and specificity did not change significantly with 71.1% (95% CI 466 68.5 to 73.6) and 98.9% (95% CI 98.6 to 99.1), respectively. If studies that could have potentially been 467 influenced by test manufacturers were excluded, sensitivity decreased marginally, but with overlapping confidence intervals (sensitivity of 70.3% [95% CI 67.6 to 72.9] and specificity of 99.0% [95% CI 468 98.7 to 99.2]). 469

470

471 **DISCUSSION**

472 After reviewing 194 clinical accuracy studies, we found Ag-RDTs to be 76.4% (95%Cl 73.8 to 78.8) sensitive and 99.1% (95% CI 98.8 to 99.3) specific in detecting SARS-CoV-2 compared to RT-PCR when 473 performed according to manufacturers' instructions. Viral load as estimated by Ct-value was the de-474 475 ciding factor for sensitivity, confirming prior work [11]. There was a significant correlation between 476 test sensitivity and Ct-value, with sensitivity increasing by 2.9 percentage points for every unit decrease 477 in mean Ct-value when controlling for symptom status and testing procedure. The pooled Ct-value for 478 TP was on average over 8 points lower than for FN results (Ct-value of 22.2 for TP compared to 30.4 479 for FN results). A decrease in performance when not following manufacturer's instructions was sug-480 gested but was not significant (-5.2 percentage points [95% CI -13.0 to 2.6]).

481 Furthermore, sensitivity was found to be higher when samples were from symptomatic (76.2% 482 sensitivity) compared to asymptomatic participants (56.8% sensitivity). This was confirmed in the re-483 gression model, estimating sensitivity to be 20.0 percentage points higher in samples that originated 484 from symptomatic participants. In our previous analysis, we assumed that the increase in sensitivity is 485 not due to the symptom status as such, but results from the fact that in symptomatic study populations 486 chances are higher to include participants at the beginning of the disease with high viral load [4]. In 487 the present analysis, this assumption shows to be largely true. Controlling for Ct-value, the RT-PCR 488 correlate for viral load, the effect of symptomatic vs. asymptomatic participants on test sensitivity 489 strongly decreased to 11.1 percentage points. As others found symptomatic and asymptomatic indi-490 viduals to have the same viral load when at the same stage of the disease [6], we would have expected 491 the regression coefficient to have decreased even further to 0. This non-zero difference in sensitivity 492 between symptomatic and asymptomatic participants may be due to the lack of access to individual participant Ct-values, which required our analyses to control for the mean Ct-value over all participants 493 494 in a data set rather than the individual Ct-values. Furthermore, some variability is likely introduced by 495 the testing for the Ag-RDT and the RT-PCR not to occur from the sample. Therefore, some degree of 496 residual confounding is likely present.

497 We also found sensitivity to be higher when participants were tested within 7 days of symptom 498 onset (81.9% sensitivity) compared to > 7 days (51.8% sensitivity). Concordantly, our regression model 499 estimated that sensitivity decreases by 3.2 percentage points for every 1 day increase in mean symp-500 tom duration. Again, this decrease in sensitivity is driven by viral load as was seen when controlling for 501 Ct-value. Importantly, it is not yet clear how the emergence of new SARS-CoV-2 variants of concern 502 and the growing vaccination coverage will affect Ag-RDTs sensitivity in the early days after symptom 503 onset. Most of the studies included in this analysis were performed at the time the wildtype and Alpha 504 variant were circulating. While data confirmed similar Ag-RDT sensitivity in the Delta variant compared 505 to wildtype, for the Omicron SARS-CoV-2 variant the first data in analytical studies suggests similar and 506 possibly lower performance [212, 213]. Vaccination did not affect viral kinetics in the first week [214] 507 and is unlikely to do so for the Omicron variant [215]. To further inform public health decision makers 508 on the best strategy to apply Ag-RDTs, clinical accuracy studies in settings with high prevalence of the 509 Omicron variant are urgently needed.

510 Looking at specific tests, LumiraDx and Standard Q nasal showed the highest sensitivity, perform-511 ing above the 80% sensitivity target defined by the World Health Organization. However, while the 512 Standard Q nasal was 99.1% (95% CI 98.4 to 99.5) specific, the LumiraDx only had a specificity of 96.9% 513 (95% CI 94.4-98.3), which is just below the WHO target of 97%. The reason for the lower specificity is 514 unclear, particularly as independent analytical studies also confirmed the test had no cross-reactivity 515 [102]. Sample to sample variability must be considered, particularly as the sensitivity of the index tests 516 approaches that of the reference test. The 2 most often evaluated tests, namely Panbio (32,370 sam-517 ples; sensitivity of 71.9%) and Standard Q (35,664 samples; sensitivity of 70.9%), performed slightly 518 below the overall average. Similarly, Panbio and Standard Q were also the most extensively evaluated 519 Ag-RDTs in the prior analysis, and with a sensitivity slightly above average [4]. Nonetheless, this up-520 dated analysis indicates that there is limited added value is to be expected from any further analysis 521 of Ag-RDTs' overall sensitivity or the sensitivity of the most widely-evaluated tests. However, it will be 522 important to continue to reassess tests' analytical sensitivity for detection of new specific variants

(e.g., Omicron). Also, it would be of interest to evaluate the characteristics of specific formats of AgRDTs, such as Ag-RDTs that are self-performed or those that are instrument-based.

525 Furthermore, sensitivity strongly differed between studies that conducted the Ag-RDTs as per 526 manufacturer's instructions and those that did not (sensitivity of 66.7% for not IFU-conforming vs. 527 76.4% for IFU-conforming). With regards to sample types, saliva showed a markedly lower sensitivity 528 of 50.1%, compared to NP or AN/MT samples, confirming what we found in our previous analysis [4]. 529 Especially in light of the current debate on whether saliva or throat swabs might be a more sensitive 530 sample to detect the SARS-CoV-2 Omicron variant than NP or AN/MT samples [216-218], further re-531 search is urgently needed to quantify the difference in viral load resulting from different sample types 532 and thus the effect of sample type on test sensitivity.

In concordance with the above, many studies reporting an unusually low sensitivity performed the Ag-RDT not as per IFU [26, 28, 40, 66, 97, 108, 133, 184] or used saliva samples [20, 150, 155, 219]. However, 2 studies with IFU-conforming testing procedure on NP or AN/MT sample, still showed a low sensitivity. This quite likely results from the on average low viral load in 1 study [49], and the asymptomatic study population in the other [175]. On the contrary, compared to the other studies unusual high sensitivity was found in studies where average viral load was high [45, 84, 144, 145] or participants were mainly within the first week of symptom onset [42, 54, 135].

540 The main strength of our study lies in its living approach. The ability to update our methodology 541 as the body of evidence grows has enabled more improved analysis. For example, while data were too 542 heterogenous for a meta-regression during the prior analysis, with additional datasets we are now able 543 to analyze the relationship between an Ag-RDT's sensitivity, the samples' Ct-value, and the partici-544 pants' symptom status in depth. Similarly, we decided to focus on clinical accuracy studies for POC Ag-545 RDTs in this current review as analytical accuracy studies require a dedicated approach to be compa-546 rable. Furthermore, the main results of our latest extractions are publicly available on our website. 547 This has not only equipped public health professionals with an up-to-date overview on the current

research landscape [220, 221], but also led other researchers and the test manufacturers to check our
data, improving the quality of our report through continuous peer-review.

550 Nonetheless, our study is limited in that we use RT-PCR as a reference standard to assess the 551 accuracy of Ag-RDTs, which might be a less appropriate reference standard than viral culture [135, 552 222]. However, viral culture is available in research settings only and its validity as a true proxy of actual 553 transmissibility is not proven, therefore we find RT-PCR a suitable reference standard for the clinical 554 accuracy studies included in this review. Furthermore, we fully acknowledge that Ct-value is not equiv-555 alent to viral load, and that the correlation between Ct-value and viral load varies between RT-PCR 556 assays; nonetheless, we believe that the analysis of pooled Ct-value data across a very large data set 557 is a useful strategy to understand the overall contribution of viral load to Ag-RDT performance. Finally, 558 we are aware that the test specific sensitivities and specificities can be influenced by differences in study design. However, we aimed to counterbalance this effect by assessing relevant aspects in study 559 560 design for each study and analyzing outliers. To enhance comparability in between clinical accuracy 561 studies, future studies should include individuals at a similar stage in the disease, use the same sample 562 types and adhere to the WHO standard for measuring SARS-CoV-2 viral load [12].

563

564 CONCLUSION

565 In summary, Ag-RDTs detect most of the persons infected with SARS-CoV-2 when performed ac-566 cording to the manufacturers' instructions. While this confirms the results of our previous analysis, the 567 present analysis highlights that the sample's viral load is the most influential factor underlying test 568 sensitivity. Thus, Ag-RDTs can play a vital role in detecting persons with high viral load and therefore 569 likely to be at highest risk of transmitting the virus. This holds true even in the absence of patient 570 symptoms or differences in the duration of symptoms. To foster further research analyzing specific Ag-571 RDTs and the factors influencing their sensitivity in more detail, standardization of clinical accuracy 572 studies and access to patient level Ct-value and duration of symptoms are essential.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.11.22270831; this version posted February 15, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

573 **REFERENCES**

- World Health Organization, Recommendations for national SARS-CoV-2 testing strategies and 574 1. 575 diagnostic capacities. No. WHO/publications/i/item/WHO-2019-nCoV-lab-testing-2021.1-576 eng, 2021. 577 Dinnes, J., et al., Rapid, point-of-care antigen and molecular-based tests for diagnosis of 2. 578 SARS-CoV-2 infection. Cochrane Database of Systematic Reviews, 2021. 3: p. CD013705. 579 3. World Health Organization, Antigen-detection in the diagnosis of SARS-CoV-2 infection. WHO 580 Reference Number: WHO/2019-nCoV/Antigen_Detection/2021.1, 2021. 581 4. Brümmer, L.E., et al., Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living 582 systematic review and meta-analysis. PLoS Medicine, 2021. 18(8): p. e1003735.
- 5835.Nehme, M., et al., COVID-19 Symptoms: Longitudinal Evolution and Persistence in Outpatient584Settings. Ann Intern Med, 2021. 174(5): p. 723-725.
- 5856.Kissler, S.M., et al., Viral dynamics of acute SARS-CoV-2 infection and applications to586diagnostic and public health strategies. PLoS Biol, 2021. 19(7): p. e3001333.
- 587 7. Wang, Y., et al., *Kinetics of viral load and antibody response in relation to COVID-19 severity*. J
 588 Clin Invest, 2020. **130**(10): p. 5235-5244.
- 5898.Leeflang, M.M., et al., Systematic reviews of diagnostic test accuracy. Annals of Internal590Medicine, 2008. 149(12): p. 889-97.
- 5919.Moher, D., et al., Preferred reporting items for systematic reviews and meta-analyses: the592PRISMA statement. Annals of Internal Medicine, 2009. **151**(4): p. 264-9, W64.
- 59310.World Health Organization, Antigen-detection in the diagnosis of SARS-CoV-2 infection:594interim guidance, 6 October 2021. WHO/2019-nCoV/Antigen_Detection/2021.1, 2021.
- Pollock, N., et al., Correlation of SARS-CoV-2 Nucleocapsid Antigen and RNA Concentrations in
 Nasopharyngeal Samples from Children and Adults Using an Ultrasensitive and Quantitative
 Antigen Assay. Journal of Clinical Microbiology, 2020. 59: p. e03077-20.
- 59812.World Health Organization, First WHO International Standard for SARS-CoV-2 RNA. Version5993.0, Dated 11/02/2021, 2021.
- McGrath, S., et al., *Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis.* Stat Methods Med Res, 2020: p. 962280219889080.
 Viechtbauer, W., *Conducting Meta-Analyses in R with the metafor Package.* Journal of
- 602 14. Viechtbauer, W., Conducting Meta-Analyses in R with the metafor Package. Jo 603 Statistical Software, 2010. **36**(3): p. 1–48.
- 60415.van Enst, W.A., et al., Investigation of publication bias in meta-analyses of diagnostic test605accuracy: a meta-epidemiological study. BMC Med Research Methodology, 2014. 14: p. 70.
- Abdul-Mumin, A., et al., *Field evaluation of specificity and sensitivity of a standard SARS-CoV- 2 antigen rapid diagnostic test: A prospective study at a teaching hospital in Northern Ghana.*medRxiv [Preprint]; published September 17, 2021.
- 60917.Abdulrahman, A., et al., Comparison of SARS-COV-2 nasal antigen test to nasopharyngeal RT-610PCR in mildly symptomatic patients. medRxiv [Preprint]; published December 08, 2020.
- Abusrewil, Z., et al., *Time scale performance of rapid antigen testing for SARS-COV-2: evaluation of ten rapid antigen assays.* Journal of Medical Virology, 2021: p. 1-7.
- 613 19. Agarwal, J., et al., "David vs. Goliath": A simple antigen detection test with potential to
 614 change diagnostic strategy for SARS-CoV-2. Journal of Infection in Developing Countries,
 615 2021. 15(7): p. 904-909.
- 61620.Agulló, V., et al., Evaluation of the rapid antigen test Panbio COVID-19 in saliva and nasal617swabs: A population-based point-of-care study. Journal of Infection, 2020. 82(5): p. 186-230.
- Akashi, Y., et al., *Evaluation and clinical implications of the time to a positive results of antigen testing for SARS-CoV-2.* medRxiv [Preprint]; published June 13, 2021.
- Akingba, O.L., K. Sprong, and D.R. Hardie, *Field performance evaluation of the PanBio rapid SARS-CoV-2 antigen assay in an epidemic driven by 501Y.v2 (lineage B.1.351) in the Eastern Cape, South Africa.* Journal of Clinical Virology Plus, 2021. 1(1-2): p. 100013.

625 Inflection, 2020. 27 (3): p. 472.010.	
626 24. Alemany, A., et al., Analytical and Clinical Performance of the Panbio COVID-19 Antigen-	
627 Detecting Rapid Diagnostic Test. Journal of Infection, 2020. 82 (5): p. 186-230.	
628 25. Allan-Blitz, L.T. and J.D. Klausner, A Real-World Comparison of SARS-CoV-2 Rapid Antige	n vs.
629 <i>Polymerase Chain Reaction Testing in Florida.</i> Journal of Clinical Microbiology, 2021. 59	10):
630 p. e0110721.	
631 26. Baccani, I., et al., Evaluation of Three Immunoassays for the Rapid Detection of SARS-Co	V-2
632 Antigens. Diagnostic Microbiology and Infectious Disease, 2021. 101 (2): p. 115434.	
633 27. Bachman, C.M., et al., Clinical validation of an open-access SARS-COV-2 antigen detection	n
634 <i>lateral flow assay, compared to commercially available assays.</i> PLoS One, 2021. 16(8): p	
635 e0256352.	
636 28. Baro, B., et al., Performance characteristics of five antigen-detecting rapid diagnostic te	st
637 (Aa-RDT) for SARS-CoV-2 asymptomatic infection: a head-to-head benchmark compariso	on.
638 Journal of Infection, 2021, 82 (6): p. 269-275.	
639 29 Beck E.T., et al. Comparison of Quidel Sofia SARS FIA Test to Hologic Antima SARS-CoV-	2
640 TMA Test for Diagnosis of COVID-19 in Symptomatic Outpatients Journal of Clinical	-
641	
642 30 Berger A et al Diagnostic accuracy of two commercial SARS_CoV-2 Antigen-detecting	ranid
642 50. Derger, A., et al., Diagnostic accuracy of two commercial SANS-COV-2 Antigen-detecting	lupiu
644 E0240521.	c of
645 51. Blanco, G., et al., Evaluation of an antigen-based test for hospital point-of-care alagnosi	s 0j
546 SARS-COV-2 Injection. Journal of Clinical Virology, 2021. 139 : p. 104838.	
647 32. Biairon, L., et al., <i>Efficacy comparison of three rapid antigen tests for SARS-Cov-2 and no</i>	W
648 Viral load impact their performance. Journal of Medical Virology, 2021. 93: p. 5783-5788	.
649 33. Bornemann, L., et al., <i>Real-life evaluation of the Sofia SARS-CoV-2 antigen assay in a lar</i>	је
650 <i>tertiary care hospital.</i> Journal of Clinical Virology, 2021. 140 : p. 104854.	
651 34. Bouassa, M.R.S., et al., Analytical performances of the point-of-care SIENNA [™] COVID-19	
652 Antigen Rapid Test for the detection of SARS-CoV-2 nucleocapsid protein in nasopharyng	eal
653 <i>swabs: A prospective evaluation during the COVID-19 second wave in France.</i> Internatio	nal
Journal of Infectious Diseases, 2021. 106 : p. 8-12.	
655 35. Brihn, A., et al., <i>Diagnostic Performance of an Antigen Test with RT-PCR for the Detectio</i>	n of
656 SARS-CoV-2 in a Hospital Setting - Los Angeles County, California, June-August 2020.	
657 Morbidity and Mortality Weekly Report, 2021. 70 (19): p. 702-706.	
658 36. Bruzzone, B., et al., Comparative diagnostic performance of different rapid antigen dete	ction
659 <i>tests for COVID-19 in the real-world hospital setting.</i> International Journal of Infectious	
660 Diseases, 2021. 107 : p. 215-218.	
661 37. Bulilete, O., et al., Panbio [™] rapid antigen test for SARS-CoV-2 has acceptable accuracy in	1
662 <i>symptomatic patients in primary health care.</i> Journal of Infection, 2021. 82 : p. 391-398.	
663 38. Caramello, V., et al., Are antigenic tests useful for detecting SARS-CoV-2 infections in particular	ients
664 accessing to emergency departments? Results from a North-West Italy Hospital. Journal	of
665 Infection, 2021. 83 : p. 237-279.	
666 39. Carbonell-Sahuquillo, S., et al., Evaluation of a rapid antigen detection test (Panbio [™] CC	VID-
667 19 Aa Rapid Test Device) as a point-of-care diagnostic tool for COVID-19 in a Pediatric	
668 <i>Emergency Department</i> , Journal of Medical Virology, 2021; p. 1-5.	
669 40 Caruana G. et al. ImplemeNting SARS-CoV-2 Rapid antigen testing in the Emergency w	Ard
670 of a Swiss univErsity hospital: the INCREASE study microorganisms 2021 9 (4): p. 798	
671 41. Caruana, G., et al., The dark side of SARS-CoV-2 ranid antigen testing: screening	
672 asymptomatic nations New Microhes and New Infections 2021 42 n 100899	
673 42 Cassuto N.G. et al. Evaluation of a SARS-CoV-2 antigen-detecting ranid diagnostic test	as a
674 <i>self-test: diagnostic performance and usability.</i> Journal of Medical Virology. 2021: p. 1-7	

675 676 677	43.	Cento, V., et al., <i>Frontline Screening for SARS-CoV-2 Infection at Emergency Department</i> Admission by Third Generation Rapid Antigen Test: Can We Spare RT-qPCR? Viruses-Basel, 2021. 13 (5): p. 818.
678 679 680	44.	Cerutti, F., et al., Urgent need of rapid tests for SARS CoV-2 antigen detection: Evaluation of the SD-Biosensor antigen test for SARS-CoV-2. Journal of Clinical Virology, 2020. 132 : p. 104654.
681 682	45.	Chaimayo, C., et al., <i>Rapid SARS-CoV-2 antigen detection assay in comparison with real-time</i> <i>RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand</i> . Virology Journal, 2020. 17 (1):
684 685 686	46.	Chiu, R., et al., Evaluation of the INDICAID COVID-19 Rapid Antigen Test in symptomatic populations and asymptomatic community testing. Microbiology Spectrum, 2021. 9 (1): p. e0034221
687 688	47.	Christensen, K., et al., Clinical evaluation of BD Veritor [™] SARS-CoV-2 and Flu A+B Assay for point-of-care (POC) System. medRxiv [Preprint]; published May 05, 2021.
689 690	48.	Ciotti, M., et al., <i>Performance of a rapid antigen test in the diagnosis of SARS-CoV-2 infection</i> . Journal of Medical Virology, 2021. 93 : p. 2988–2991.
691 692	49.	Dankova, Z., et al., Comparison of SARS-CoV-2 Detection by Rapid Antigen and by Three Commercial RT-qPCR Tests: A Study from Martin University Hospital in Slovakia. International
693 694	50.	Journal of Environmental Research and Public Health, 2021. 18 (13). Del Vecchio, C., et al., <i>Emergence of N antigen SARS-CoV-2 genetic variants escaping</i>
695 696	51.	Di Domenico, M., et al., Diagnostic Accuracy of a New Antigen Test for SARS-CoV-2 Detection.
697 698	52.	International Journal of Environmental Research and Public Health, 2021. 18 (12): p. 6310. Dierks, S., et al., <i>Diagnosing SARS-CoV-2 with Antigen Testing, Transcription-Mediated</i>
699 700 701	53.	Amplification and Real-Time PCR. Journal of Clinical Medicine, 2021. 10 (11): p. 2404. Domínguez Fernández, M., et al., <i>Experience with Panbio rapid antigens test device for the</i> <i>detection of SARS-CoV-2 in nursing homes</i> . Enfermedades Infecciosas y Microbiología Clínica,
702 703 704	54.	2021. S0213-005X . Drain, P.K., et al., <i>A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid</i> <i>Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance Study</i> . Infectious
705 706	55.	Diseases and Therapy, 2021. 10 (2): p. 753–761. Drevinek, P., et al., <i>The sensitivity of SARS-CoV-2 antigen tests in the view of large-scale</i>
707 708	56.	<i>testing</i> . medRxiv [Preprint]; published November 24, 2020. Eleftheriou, I., et al., <i>Real-life evaluation of a COVID-19 rapid antigen detection test in</i>
709 710	57.	hospitalized children. Journal of Medical Virology, 2021. Escrivá, B.F., et al., The effectiveness of rapid antigen test-based for SARS-CoV-2 detection in
711 712	58.	nursing homes in Valencia, Spain. Journal of Clinical Virology, 2021. 143 : p. 104941. Faíco-Filho, K.S., et al., <i>Evaluation of the Panbio™ COVID-19 Ag Rapid Test at an Emergency</i>
713 714 715	59.	Room in a Hospital in São Paulo, Brazil. medRxiv [Preprint]; published March 24, 2021. Favresse, J., et al., Head-to-Head Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-CoV-2 Infection. Journal of Clinical Medicine, 2021. 10 (2): p.
716 717 718	60.	265. Fenollar, F., et al., <i>Evaluation of the Panbio Covid-19 rapid antigen detection test device for</i> <i>the screening of patients with Covid-19.</i> Journal of Clinical Microbiology, 2020. 59 : p. e02589-
719 720 721	61.	20. Ferguson, J., et al., Validation testing to determine the sensitivity of lateral flow testing for asymptomatic SARS-CoV-2 detection in low prevalence settings: Testing frequency and public
722 723 724	62.	health messaging is key. PLoS Biol, 2021. 19 (4): p. e3001216. Fernández, M.D., et al., Usefulness of the LumiraDx SARS-COV-2 antigen test in nursing home. Enfermedades Infecciosas y Microbiología Clínica, 2021.

725	63.	Fernandez-Montero, A., et al., Validation of a rapid antigen test as a screening tool for SARS-
726		CoV-2 infection in asymptomatic populations. Sensitivity, specificity and predictive values.
727		EClinicalMedicine, 2021. 37 : p. 100954.
728	64.	Ferté, T., et al., Accuracy of COVID-19 rapid antigenic tests compared to RT-PCR in a student
729		population: The StudyCov study. Journal of Clinical Virology, 2021. 141 : p. 104878.
730	65.	Filgueiras, P., et al., COVID-19 Rapid Antigen Test at hospital admission associated to the
731		knowledge of individual risk factors allow overcoming the difficulty of managing suspected
732		patients in hospitals COVID-19 Rapid Antigen Test facilitates the management of suspected
733		patients on hospital admission. medRxiv [Preprint]; published January 08, 2021.
734	66.	Fourati, S., et al., Performance of six rapid diagnostic tests for SARS-CoV-2 antigen detection
735		and implications for practical use. Journal of Clinical Virology. 2021. 142 : p. 104930.
736	67.	Frediani, J.K., et al., Multidisciplingry assessment of the Abbott BingxNOW SARS-CoV-2 point-
737	••••	of-care antiaen test in the context of emeraina viral variants and self-administration. Sci Rep.
738		2021 11 (1): n 14604
739	68	García-Fiñana, M., et al., Performance of the Innova SARS-CoV-2 antigen ranid lateral flow
740	00.	test in the Livernool asymptomatic testing nilot: nonulation based cohort study. British
740		Medical Journal 2021 374 : p. p1637
741	69	Gomez Marti II et al Differences in detected viral loads quide use of SARS-CoV-2 antigen-
742	09.	detection accaus towards sumptomatic college students and children modPyin [Droprint]:
745		nublished February 01, 2021
744	70	Crommols H ot al Real life validation of the Danhie COVID 10 Antigen Ranid Test (Abbett)
745	70.	in community dwalling subjects with sumptoms of notantial SARS CoV 2 infection
740		In community-awening subjects with symptoms of potential SARS-Cov-2 Injection.
747	74	Eclinicaliviedicine, 2020. 31 : p. 100677.
748	/1.	Gupta, A., et al., <i>Rapid chromatographic immunoassay-based evaluation of COVID-19:</i> A
749		cross-sectional, alagnostic test accuracy study & its implications for COVID-19 management
750	70	<i>In India</i> . Indian Journal of Medical Research, 2020. 153 (1): p. 126.
751	72.	Halton, P., et al., An optimized stepwise digorithm combining rapid antigen and RT-qPCR for
/52		screening of COVID-19 patients. PLoS ONE, 2021. 16 (9): p. e0257817.
753	/3.	Harris, D.I., et al., SARS-CoV-2 Rapid Antigen Testing of Symptomatic and Asymptomatic
754		Individuals on the University of Arizona Campus. Biomedicines, 2021. 9 (5): p. 539.
755	74.	Herrera, V., et al., Testing of Healthcare Workers Exposed to COVID19 with Rapid Antigen
756		Detection. medRxiv [Preprint]; published August 18, 2020.
757	75.	Holzner, C., et al., SARS-CoV-2 rapid antigen test: Fast-safe or dangerous? An analysis in the
758		<i>emergency department of an university hospital.</i> Journal of Medical Virology, 2021. 93 : p.
759		5323–5327.
760	76.	Homza, M., et al., Five Antigen Tests for SARS-CoV-2: Virus Viability Matters. Viruses, 2021.
761		13 (4).
762	77.	Homza, M., et al., Covid-19 antigen testing: better than we know? A test accuracy study.
763		Infectious Diseases, 2021. 53(9): p. 661-668.
764	78.	Houston, H., et al., Diagnostic accuracy and utility of SARS-CoV-2 antigen lateral flow assays
765		in medical admissions with possible COVID-19. Journal of Hospital Infection, 2021. 110: p.
766		203-205.
767	79.	Ifko, M. and M. Skvarc, Use of Immunochromatographic SARS-CoV-2 Antigen Testing in Eight
768		Long-Term Care Facilities for the Elderly. Healthcare, 2021. 9(7): p. 868.
769	80.	Iglòi, Z., et al., Clinical evaluation of the Roche/SD Biosensor rapid antigen test with
770		symptomatic, non-hospitalized patients in a municipal health service drive-through testing
771		site. Emerging Infectious Diseases, 2020. 27(5): p. 1323-1329.
772	81.	Jääskeläinen, A.E., et al., Evaluation of three rapid lateral flow antigen detection tests for the
773		diagnosis of SARS-CoV-2 infection. Journal of Clinical Virology, 2021. 137: p. 104785.
774	82.	James, A.E., et al., Performance of the BinaxNOW COVID-19 Antigen Card test relative to the
775		SARS-CoV-2 real-time reverse transcriptase polymerase chain reaction assay among

776		symptomatic and asymptomatic healthcare employees. Infection Control and Hospital
777		Epidemiology, 2021: p. 1-3.
778 779	83.	Jegerlehner, S., et al., <i>Diagnostic accuracy of a SARS-CoV-2 rapid antigen test in real-life clinical settings</i> . International Journal of Infectious Diseases, 2021. 109 : p. 118-122.
780 781	84.	Johnson, C., et al., Evaluation of the Panbio SARS-CoV-2 rapid antigen detection test in the
701	05	Bunumus, meanxiv (Preprint); published July 15, 2021.
782 783	85.	Life Study. Frontiers in Pediatrics, 2021. 9 : p. 647274.
784	86.	Kahn, M., et al., Performance of antigen testing for diagnosis of COVID-19: a direct
785		comparison of a lateral flow device to nucleic acid amplification based tests. BMC Infect Dis,
786		2021. 21 (1): p. 798.
787	87.	Kanaujia, R., et al., Rapid antigen detection kit for the diagnosis of SARS-CoV-2 - are we
788		missing asymptomatic patients? Indian Journal of Medical Microbiology, 2021.
789	88.	Kannian, P., et al., SARS-CoV2 antigen in whole mouth fluid may be a reliable rapid detection
790		<i>tool.</i> Oral Diseases, 2021. 00 : p. 1-2.
791	89.	Karon, B.S., et al., Analytical sensitivity and specificity of four point of care rapid antigen
792		diagnostic tests for SARS-CoV-2 using real-time quantitative PCR, quantitative droplet digital
793		PCR, and a mass spectrometric antigen assay as comparator methods. Clinical Chemistry,
794		2021. hvab138.
795	90.	Kenyeres, B., et al., Comparison of four PCR and two point of care assays used in the
796		laboratory detection of SARS-CoV-2. Journal of Virological Methods, 2021. 293: p. 114165.
797	91.	Kernéis, S., et al., Accuracy of saliva and nasopharyngeal sampling for detection of SARS-CoV-
798		2 in community screening: a multicentric cohort study. European Journal of Clinical
799		Microbiology & Infectious Diseases, 2021: p. 1-10.
800	92.	Kilic, A., B. Hiestand, and E. Palavecino, <i>Evaluation of Performance of the BD Veritor SARS</i> -
801		CoV-2 Chromatographic Immunoassay Test in Patients with Symptoms of COVID-19. Journal
802		of Clinical Microbiology, 2021. 59(5).
803	93.	Kim, D., et al., Development and Clinical Evaluation of an Immunochromatography-Based
804		Rapid Antigen Test (GenBody (TM) COVAG025) for COVID-19 Diagnosis. Viruses-Basel, 2021.
805		13 (5).
806	94.	Kim, H.W., M. Park, and J.H. Lee, Clinical Evaluation of the Rapid STANDARD Q COVID-19 Ag
807		Test for the Screening of Severe Acute Respiratory Syndrome Coronavirus 2. Annals of
808		Laboratory Medicine, 2022. 42 (1): p. 100-104.
809	95.	Kipritci, Z., et al., Evaluation of a Visually-Read Rapid Antigen Test Kit (SGA V-Chek) for
810		Detection of SARS-CoV-2 Virus. Mikrobiyoloji Bulteni, 2021. 55(3): p. 461-464.
811	96.	Koeleman, J.G.M., et al., Clinical evaluation of rapid point-of-care antigen tests for diagnosis
812		of SARS-CoV-2 infection. European Journal of Clinical Microbiology & Infectious Diseases,
813		2021: p. 1-7.
814	97.	Kohmer, N., et al., The Comparative Clinical Performance of Four SARS-CoV-2 Rapid Antigen
815		Tests and Their Correlation to Infectivity In Vitro. Journal of Clinical Medicine, 2021. 10(2).
816	98.	Kolwijck, E., et al., Validation and implementation of the Panbio COVID-19 Ag rapid test for
817		the diagnosis of SARS-CoV-2 infection in symptomatic hospital healthcare workers. Infection
818		Prevention in Practice, 2021. 3 (2): p. 100142.
819	99.	Korenkov, M., et al., Evaluation of a rapid antigen test to detect SARS-CoV-2 infection and
820		<i>identify potentially infectious individuals</i> . Journal of Clinical Microbiology, 2021. 59 (9): p.
821		e0089621.
822	100.	Krüger, L.J., et al., Evaluation of the accuracy, ease of use and limit of detection of novel,
823		rapid, antigen-detecting point-of-care diagnostics for SARS-CoV-2. medRxiv [Preprint];
824		published October 04, 2020.
825	101.	Krüger, L.J., et al., The Abbott PanBio WHO emergency use listed, rapid, antigen-detecting
826		point-of-care diagnostic test for SARS-CoV-2-Evaluation of the accuracy and ease-of-use. PLoS
827		ONE, 2021. 16 (5): p. e0247918.

 Krüttgen, A., et al., <i>Comparison of the SARS-COV-2 Rapid antigen test to the real star Sars-CoV-2 RT PCR kit.</i> Journal of Virological Methods, 2020. 28: p. 114024. Kumar, K.K., et al., <i>Pre-Operative SARS CoV-2 Rapid Antigen Test and Reverse Transcription Polymerase Chain Reaction: A conundrum in surgical decision making.</i> Indian Journal of Ophthalmology, 2021. 69(i): p. 1560-1562. Kurihara, Y., et al., <i>The evaluation of a novel digital immunochromatographic assay with silver amplification to detect SARS-CoV-2.</i> Journal of Infection and Chemotherapy, 2021. 19(9): p. 1993-1497. L'Huillier, A., et al., <i>Diagnostic accuracy of SARS-CoV-2 rapid antigen detection testing in symptomatic and asymptomatic children in the clinical setting.</i> Journal of Clinical Microbiology, 2021. 59(8): p. e0091-21. Lambert-Niclot, S., et al., <i>Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeol Swabs.</i> Journal of Clinical Microbiology, 2020. 58(8): p. e0097-20. Lee, J., et al., <i>Clinical Performance of the Standard Q COVID-19 Rapid Antigen Test and Simulation of its Real-World Application in Korea.</i> Annals of Laboratory Medicine, 2021. 41(6): p. 588-592. Leixner, G., et al., <i>Evaluation of the SARS-CoV-2 rapid antigen test in a hospital setting.</i> International Journal of Infectious Diseases, 2021. 108: p. 353-356. Leikner, A., et al., <i>Parlomance of a SARS CoV-2 antigen rapid immunoassy in patients admitted to the Emergency Department.</i> International Journal of Clinical Virology, 2020. 138(1): 110: p. 135-140. Linares, M., et al., <i>Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 doxy after the onset of symptors.</i> Journal of Clinical Virology, 2021. 10(2): 51(5): p. 2004430. Lindner, A.K., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab versus profession</i>	828 829	102.	Krüger, L.J., et al., <i>Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use of LumiraDx: An antigen-detecting point-of-care device for SARS-CoV-2.</i> Infection, 2021: p. 1-12.
 Kumar, K.K., et al., <i>Pre-Operative SARS CoV-2 Rapid Antigen Test and Reverse Transcription</i> <i>Polymerase Chain Reaction: A conundrum in surgical decision making.</i> Indian Journal of Ophthalmology, 2021. 69(6): p. 1560-1562. Kurihara, Y., et al., <i>The evaluation of a novel digital immunochromatographic assy with</i> <i>silver amplification to detect SARS-CoV-2.</i> Journal of Infection and Chemotherapy, 2021. 27(10): p. 1493-1497. L'Huillier, A., et al., <i>Diagnostic accuracy of SARS-CoV-2 rapid antigen detection testing in</i> <i>symptomatic and asymptomatic children in the clinical setting.</i> Journal of Clinical Microbiology, 2021. 59(9): p. e00991-21. Lambert-Niclot, S., et al., <i>Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2</i> <i>Antigen in Nasopharyngeal Swabs.</i> Journal of Clinical Microbiology, 2020. 58(8): p. e00977- 20. Lee, J., et al., <i>Clinical Performance of the Standard Q COVID-19 Rapid Antigen Test and Simulation of its Real-World Application in Korea.</i> Annals of Laboratory Medicine, 2021. 41(6): p. 588-592. Leikner, C., et al., <i>Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting.</i> International Journal of Infectious Diseases, 2021. 108: p. 353-356. Leikner, A., et al., <i>Performance of a SARS CoV-2 antigen rapid immunoassay in patients admitted to the Emergency Department.</i> International Journal of Clinical Virology, 2020. 133: p. 104659. Linares, M., et al., <i>Pando antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days offer the onset of symptoms.</i> Journal of Clinical Virology, 2020. 133: p. 104659. Lindner, A.K., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with professional-collected nasol versus professional-collected nasopharyngeal swab.</i> European Respiratory Journal, 2020. 57(5): p. 2004430. Lindner, A.K., et al., <i>Bardoto-head comparison of SARS-CoV-2 antigen-detecting rapid test</i> <i></i>	830 831	103.	Krüttgen, A., et al., <i>Comparison of the SARS-CoV-2 Rapid antigen test to the real star Sars-</i> <i>CoV-2 RT PCR kit</i> . Journal of Virological Methods, 2020. 288 ; p. 114024.
 Polymerase Chain Reaction: A conundrum in surgical decision making. Indian Journal of Optithalmology, 2021. 69(6): p. 1560-1562. Kurihara, Y., et al., The evaluation of a novel digital immunochromatographic assay with silver amplification to detect SARS-CoV-2. Journal of Infection and Chemotherapy, 2021. 27(10): p. 1493-1497. LiHuillier, A., et al., Diagnostic accuracy of SARS-CoV-2 rapid antigen detection testing in symptomatic and asymptomatic children in the clinical setting. Journal of Clinical Microbiology, 2021. 59(9): p. e00991-21. Lambert-Niclot, S., et al., Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs. Journal of Clinical Microbiology, 2020. 58(8): p. e00977- 20. Lee, I., et al., Clinical Performance of the Standard Q COVID-19 Rapid Antigen Test and Simulation of its Real-World Application in Korea. Annals of Laboratory Medicine, 2021. 41(6): p. 588-592. Leixner, G., et al., Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting. International Journal of Infectious Diseases, 2021. 108: p. 353-356. Lei, C., et al., Performance of a SARS CoV-2 antigen rapid immunoassay in patients admitted to the Emergency Department. International Journal of Infectious Diseases, 2021. 110: p. 135-140. Linares, M., et al., Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms. Journal of Clinical Virology, 2020. 133: p. 104659. Lindner, A., et al., Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal versus nrofessional-collected nasopharyngeal swab. European Respiratory Journal, 2021. 57(4). Lindner, A.K., et al., Diagnostic accuracy and feasibility of patient self-testing with a SARS- CoV-2 antigen detecting rapid test. Journal of Clinical Virology, 2021. 141: p. 104874. Lindner, A.K., et al., Diagnostic	832	104.	Kumar, K.K., et al., Pre-Operative SARS CoV-2 Rapid Antigen Test and Reverse Transcription
 Ophthalmology, 2021. 69(6): p. 1560-1562. Kurihara, Y., et al., <i>The evaluation of a novel digital immunachromatographic assay with</i> <i>silver amplification to detect SARS-CoV-2</i>. Journal of Infection and Chemotherapy, 2021. 27(10): p. 1493-1497. L'Huiller, A., et al., <i>Diagnostic accuracy of SARS-CoV-2 rapid antigen detection testing in</i> <i>symptomatic and asymptomatic children in the clinical setting</i>. Journal of Clinical Microbiology, 2021. 59(9): p. e00991-21. Lambert-Niclot, S., et al., <i>Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2</i> <i>Antigen in Nasopharyngeal Swabs</i>. Journal of Clinical Microbiology, 2020. 58(8): p. e00977- 20. Lee, J., et al., <i>Clinical Performance of the Standard Q COVID-19 Rapid Antigen Test and</i> <i>Simulation of its Real-World Application in Korea</i>. Annals of Laboratory Medicine, 2021. 41(6): p. 588-592. Leixner, G., et al., <i>Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting</i>. International Journal of Infectious Diseases, 2021. 108: p. 353-356. Leixner, G., et al., <i>Leulaution of a SARS CoV-2 antigen rapid immunoasay in patients admitted</i> to the <i>Emergency Department</i>. International Journal of Infectious Diseases, 2021. 110: p. 135-140. Linares, M., et al., <i>Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in</i> <i>the first 7 days after the onset of symptoms</i>. Journal of Clinical Virology, 2020. 133: p. 104659. Lindner, A., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test</i> <i>with self-collected nasal web versus professional-collect ansopharyngeal swab</i>. European Respiratory Journal, 2021. 57(4). Lindner, A.K., et al., <i>Mead-to-head comparison of SARS-CoV-2 antigen-detecting rapid test</i> <i>with self-collected nasal web versus professional-collect ansopharyngeal swab</i>. European Respiratory Journal, 2021. 57(4). Lindner, A.K., et al., <i>Diagnostic accuracy and feasibi</i>	833		Polymerase Chain Reaction: A conundrum in surgical decision making. Indian Journal of
 Kurihara, Y., et al., <i>The evaluation of a novel digital immunochromatographic assay with</i> <i>silver amplification to detect SARS-CoV-2</i>. Journal of Infection and Chemotherapy, 2021. 27(10): p. 1493-1497. 106. L'Huillier, A., et al., <i>Diagnostic accuracy of SARS-CoV-2 rapid antigen detection testing in</i> <i>symptomatic and asymptomatic children in the clinical setting.</i> Journal of Clinical Microbiology, 2021. 59(9): p. e00991-21. 107. Lambert-Niclot, S., et al., <i>Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2</i> <i>Antigen in Nasopharyngeal Swabs.</i> Journal of Clinical Microbiology, 2020. 58(8): p. e00977- 20. 108. Lee, J., et al., <i>Clinical Performance of the Standard Q COVID-19 Rapid Antigen Test and</i> <i>Simulation of its Real-World Application in Korea.</i> Annals of Laboratory Medicine, 2021. 109. Leixner, G., et al., <i>Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting.</i> International Journal of Infectious Diseases, 2021. 108: p. 353-356. 101. Leli, C., et al., <i>Performance of a SARS CoV-2 antigen rapid immunoassy in patients admitted</i> <i>to the Emergency Department.</i> International Journal of Clinical Virology, 2020. 133: p. 104559. 111. Linares, M., et al., <i>Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in</i> <i>the first 7 days offer the onset of symptoms.</i> Journal of Clinical Virology, 2020. 133: p. 104659. 112. Lindner, A., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with</i> <i>professional-collected nasal versus nasopharyngeal swab.</i> European Respiratory Journal, 2020. 57(5): p. 2004430. 113. Lindner, A.K., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test</i> <i>with self-collected nasal versus professional-collected nasopharyngeal swab.</i> European Respiratory Journal, 2021. 57(4). 114. Lindner, A.K., et al., <i>Diagnostic accuracy and feasibility of patient self-testin</i>	834		Ophthalmology 2021 69 (6): p. 1560-1562
 Ison Minister, Intervention of Distribution of the construction of the co	835	105	Kuribara V et al. The evaluation of a novel digital immunochromatographic assay with
 27(10): p. 1493-1497. 283 106. L'Huillier, A., et al., Diagnostic accuracy of SARS-CoV-2 rapid antigen detection testing in symptomatic and asymptomatic children in the clinical setting. Journal of Clinical Microbiology, 2021. 59(9): p. e00991-21. 207. Lambert-Niclot, S., et al., Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs. Journal of Clinical Microbiology, 2020. 58(8): p. e00977-20. 20. Lee, J., et al., Clinical Performance of the Standard Q COVID-19 Rapid Antigen Test and Simulation of its Real-World Application in Korea. Annals of Laboratory Medicine, 2021. 41(6): p. 588-592. 21. Leixner, G., et al., Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting. International Journal of Infectious Diseases, 2021. 108: p. 353-356. 210. Leixner, G., et al., Performance of a SARS CoV-2 antigen rapid immunoassay in patients admitted to the Emergency Department. International Journal of Infectious Diseases, 2021. 100: p. 353-356. 2111. Linares, M., et al., Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms. Journal of Clinical Virology, 2020. 133: p. 1046559. 2122. Lindner, A., et al., Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with professional-collected nasal versus professional-collected nasopharyngeal swab. European Respiratory Journal, 2020. 57(5): p. 2004430. 2134. Lindner, A., et al., Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal versus professional-collected nasopharyngeal swab. European Respiratory Journal, 2021. 57(4). 2134. Lindner, A., et al., Diagnostic accuracy and feasibility of patient self-testing with a SARS-CoV-2 antigen-detecting rapid test. Journal of SARS-CoV-2 in asopharyngeal sambles. Genetical nasopharyngeal samab. European Respiratory Journal, 2021. 57(4).<	836	105.	silver amplification to detect SARS-CoV-2. Journal of Infection and Chemotherapy, 2021.
 Liullier, A., et al., <i>Diagnostic accuracy of SARS-CoV-2 rapid antigen detection testing in symptomatic influer in the clinical setting.</i> Journal of Clinical Microbiology, 2021. 59(9): p. e00991-21. Lambert-Niclot, S., et al., <i>Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs.</i> Journal of Clinical Microbiology, 2020. 58(8): p. e00977-20. Lee, J., et al., <i>Clinical Performance of the Standard Q COVID-19 Rapid Antigen Test and Simulation of its Real-World Application in Korea.</i> Annals of Laboratory Medicine, 2021. 41(6): p. 588-592. Leixner, G., et al., <i>Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting.</i> International Journal of Infectious Diseases, 2021. 108: p. 353-356. Itemer, C., et al., <i>Performance of a SARS CoV-2 antigen rapid immunoassay in patients admitted to the Emergency Department.</i> International Journal of Infectious Diseases, 2021. 110: p. 135-140. Linares, M., et al., <i>Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms.</i> Journal of Clinical Virology, 2020. 133: p. 104659. Lindner, A., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with professional-collected nasal versus professional-collected nasopharyngeal swab.</i> European Respiratory Journal, 2020. 57(5): p. 2004430. Lindner, A.K., et al., <i>Diagnostic accuracy and feasibility of patient self-testing with a SARS-CoV-2 antigen-detecting rapid test with self-collected nasal wers sus professional-collected nasopharyngeal swab. European Respiratory Journal, 2015, FU, Jubidsed July 16, 2021.</i> Lindner, A.K., et al., <i>Diagnostic accuracy and feasibility of patient self-testing with a SARS-CoV-2 antigen-detecting rapid test with self-collected nasal wers sus professional-collected nasopharyngeal swab. European Respiratory Journal, 2015, FU, 2004430.</i> Lindner, A.K., et al., <i>Diagnostic </i>	837	4.00	27 (10): p. 1493-1497.
 symptomatic and asymptomatic children in the childra setting. Journal of Clinical Microbiology, 2021. 59(9): p. e00991-21. Lambert-Niclot, S., et al., Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs. Journal of Clinical Microbiology, 2020. 58(8): p. e00977-20. Lee, J., et al., <i>Clinical Performance of the Standard Q COVID-19 Rapid Antigen Test and Simulation of its Real-World Application in Korea</i>. Annals of Laboratory Medicine, 2021. 41(6): p. 588-592. Leixner, G., et al., <i>Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting</i>. International Journal of Infectious Diseases, 2021. 108: p. 353-356. ILeik, C., et al., <i>Performance of a SARS CoV-2 antigen rapid immunoassay in patients admitted to the Emergency Department</i>. International Journal of Infectious Diseases, 2021. 101: p. 135-140. Linares, M., et al., <i>Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms</i>. Journal of Clinical Virology, 2020. 133: p. 104659. Lindner, A., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with professional-collected nasal versus nasopharyngeal swab</i>. European Respiratory Journal, 2020. 57(5): p. 2004430. Lindner, A.K., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal versus professional-collected nasopharyngeal swab</i>. European Respiratory Journal, 2021. 57(4). Lindner, A.K., et al., <i>Diagnostic accuracy and feasibility of patient self-testing with a SARS-COV-2 antigen-detecting rapid test with with self-collected nasol arsab versus professional-collected nasopharyngeal swab. European Respiratory Journal, 2021. 57(4).</i> Lindner, A.K., et al., <i>Diagnostic accuracy and feasibility of patient self-testing with a SARS-COV-2 antigen-detecting rapid test</i>. Journal of Clinical Virology, 2021. 	838	106.	L Huillier, A., et al., Diagnostic accuracy of SARS-COV-2 rapid antigen detection testing in
 Microbiology, 2021. 59(9): p. e00991-21. Lambert-Nicolt, S., et al., Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs. Journal of Clinical Microbiology, 2020. 58(8): p. e00977- 20. Lee, J., et al., <i>Clinical Performance of the Standard Q COVID-19 Rapid Antigen Test and</i> Simulation of its Real-World Application in Korea. Annals of Laboratory Medicine, 2021. 41(6): p. 588-592. Leixner, G., et al., <i>Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting</i>. International Journal of Infectious Diseases, 2021. 108: p. 353-356. Lei, C., et al., <i>Performance of a SARS CoV-2 antigen rapid immunoassy in patients admitted</i> to the Emergency Department. International Journal of Infectious Diseases, 2021. 110: p. 135-140. Linares, M., et al., <i>Panbia antigen rapid test is reliable to diagnose SARS-CoV-2 infection in</i> the first 7 days after the onset of symptoms. Journal of Clinical Virology, 2020. 133: p. 104659. Lindner, A., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with</i> professional-collected nasal versus nasopharyngeal swab. European Respiratory Journal, 2020. 57(5): p. 2004430. Lindner, A.K., et al., <i>Jagnostic accuracy and feasibility of patient self-testing with a SARS-CoV-2 antigen-detecting rapid test</i> with self-collected nasal swab versus professional-collected nasopharyngeal swab. European Respiratory Journal, 2021. 57(4). Lindner, A.K., et al., <i>Diagnostic accuracy and feasibility of patient self-testing with a SARS-CoV-2 antigen-detecting rapid test</i> with self-collected ransal swab versus professional-collected nasopharyngeal samples. medRxiv [Preprint]; published July 16, 2021. Lindti, F.M., et al., <i>Performance of a novel diagnostic assay for rapid Sandary for COVID-</i> 19: Results from a Hospital Emergency Department Testing Site. Diagnostic, 2021. 11(7). Merino-Amador,	839		symptomatic and asymptomatic children in the clinical setting. Journal of Clinical
 Lambert-Nicki, S., et al., Evaluation of a Rapid Diagnostic Assay for Detection of SARS-COV-2 Antigen in Nasopharyngeal Swabs. Journal of Clinical Microbiology, 2020. 58(8): p. e00977- 20. Lee, J., et al., <i>Clinical Performance of the Standard Q COVID-19 Rapid Antigen Test and Simulation of its Real-World Application in Korea.</i> Annals of Laboratory Medicine, 2021. 41(6): p. 588-592. Leixner, G., et al., <i>Evaluation of the AMP SARS-COV-2 rapid antigen test in a hospital setting.</i> International Journal of Infectious Diseases, 2021. 108: p. 353-356. Leli, C., et al., <i>Performance of a SARS CoV-2 antigen rapid immunoassy in patients admitted</i> to the Emergency Department. International Journal of Infectious Diseases, 2021. 110: p. 1355–140. Linares, M., et al., <i>Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in</i> the first 7 days offer the onset of symptoms. Journal of Clinical Virology, 2020. 133: p. 104659. Lindner, A., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with</i> professional-collected nasal versus nasopharyngeal swab. European Respiratory Journal, 2020. 57(5): p. 2004430. Lindner, A.K., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test</i> with self-collected nasal wersus professional-collected nasopharyngeal swab. European Respiratory Journal, 2021. 57(4). Lindner, A.K., et al., <i>Diagnostic accuracy and feasibility of patient self-testing with a SARS- CoV-2 antigen-detecting rapid test.</i> Journal of Clinical Virology, 2021. 141: p. 104874. Liotti, F.M., et al., <i>Performance of a novel diagnostic assy for rapid SARS-COV-2 antigen detection in nasopharynx samples.</i> Clinical Microbiology and Infection, 2020. 27: p. 487–488. Luitar, C., et al., <i>SARS-CV-2 Antigen Detection to Expand Testing Capacity for COVID-</i> 19: Results from a Hospital Emergency Department Testing Site. Diagnostic, 2021. 143: p. 104961.<	840		Microbiology, 2021. 59 (9): p. e00991-21.
 Antigen in Nasopharyngeal Swabs. Journal of Clinical Microbiology, 2020. 58(8): p. e00977-20. Lee, J., et al., <i>Clinical Performance of the Standard Q COVID-19 Rapid Antigen Test and</i> Simulation of its Real-World Application in Korea. Annals of Laboratory Medicine, 2021. 41(6): p. 588-592. Leixner, G., et al., <i>Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting</i>. International Journal of Infectious Diseases, 2021. 108: p. 353-356. Leil, C., et al., <i>Performance of a SARS CoV-2 antigen rapid immunoassay in patients admitted</i> to the Emergency Department. International Journal of Infectious Diseases, 2021. 110: p. 135-140. Linares, M., et al., <i>Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in</i> the first 7 days after the onset of symptoms. Journal of Clinical Virology, 2020. 133: p. 104659. Lindner, A., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with</i> <i>professional-collected nasal versus nasopharyngeal swab</i>. European Respiratory Journal, 2020. 57(5): p. 2004430. Lindner, A.K., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test</i> with self-collected nasal swab versus professional-collected nasopharyngeal swab. European Respiratory Journal, 2021. 57(4). Lindner, A.K., et al., <i>Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen-detecting rapid test</i> kuect, J., et al., <i>Performance of an ingen of testing SARS-CoV-2</i> in nasopharyngeal samples. Clinical Virology 2021. 141: p. 104874. Liotti, F.M., et al., <i>Performance of an ovel diagnostic assay for rapid SARS-CoV-2</i> antigen-detecting rapid test. Lunca, c., et al., <i>Performance of an ingenid etection of SARS-CoV-2</i> in nasopharyngeal samples. Medixin y 104610. Merino-Amador, P., et al., Clinitest rapid COVID	841	107.	Lambert-Niclot, S., et al., Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2
 20. 20. 20. 20. 20. 21. 22. 23. 24. 24.	842		Antigen in Nasopharyngeal Swabs. Journal of Clinical Microbiology, 2020. 58(8): p. e00977-
 108. Lee, J., et al., <i>Clinical Performance of the Standard Q COVID-19 Rapid Antigen Test and</i> <i>Simulation of its Real-World Application in Korea.</i> Annals of Laboratory Medicine, 2021. 41(6): p. 588-592. 109. Leixner, G., et al., <i>Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting.</i> International Journal of Infectious Diseases, 2021. 108: p. 353-356. 110. Leli, C., et al., <i>Performance of a SARS CoV-2 antigen rapid immunoassay in patients admitted</i> <i>to the Emergency Department.</i> International Journal of Infectious Diseases, 2021. 110: p. 135–140. 111. Linares, M., et al., <i>Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in</i> <i>the first 7 days after the onset of symptoms.</i> Journal of Clinical Virology, 2020. 133: p. 104659. 112. Lindner, A., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with</i> <i>professional-collected nasal versus nasopharyngeal swab.</i> European Respiratory Journal, 2020. 57(5): p. 200430. 113. Lindner, A.K., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test</i> <i>with self-collected nasal swab versus professional-collected nasopharyngeal swab.</i> European Respiratory Journal, 2021. 57(4). 114. Lindner, A.K., et al., <i>Diagnostic accuracy and feasibility of patient self-testing with a SARS- CoV-2 antigen-detecting rapid test.</i> Journal of Clinical Virology, 2021. 141: p. 104874. 115. Liotti, F.M., et al., <i>Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen detection in nasopharynx samples.</i> Clinical Microbiology and Infection, 2020. 27: p. 487–488. 114. Under, A.K., et al., <i>SARS-CoV-2 Antigen Detection of SARS-COV-2 in nasopharyngeal samples.</i> medRxiv [Preprint]: published July 16, 2021. 117. Merchinelli, G., et al., <i>SARS-CoV-2 Antigen Detection to Expand Testing Capacity for COVID-</i> 19: <i>Results from a Hospital Emergency Department Testing Site.</i>	843		20.
 Simulation of its Real-World Application in Korea. Annals of Laboratory Medicine, 2021. 41(6): p. 588-592. 109. Leixner, G., et al., Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting. International Journal of Infectious Diseases, 2021. 108: p. 353-356. 110. Leli, C., et al., Performance of a SARS CoV-2 antigen rapid immunoassay in patients admitted to the Emergency Department. International Journal of Infectious Diseases, 2021. 110: p. 135-140. 111. Linares, M., et al., Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms. Journal of Clinical Virology, 2020. 133: p. 104659. 112. Lindner, A., et al., Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with professional-collected nasal versus nasopharyngeal swab. European Respiratory Journal, 2020. 57(5): p. 2004430. 113. Lindner, A.K., et al., Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab versus professional-collected nasopharyngeal swab. European Respiratory Journal, 2021. 57(4). 114. Lindner, A.K., et al., Diagnostic accuracy and feasibility of patient self-testing with a SARS- CoV-2 antigen-detecting rapid test. Journal of Clinical Virology, 2021. 141: p. 104874. 115. Liotti, F.M., et al., Performance of antigenic detection of SARS-CoV-2 in nasopharyngeal samples. medRxiv [Preprint]; published July 16, 2021. 114. Merino-Amador, P., et al., Clinitest rapid COVID-19 antigen testing Capacity for COVID- 19: Results from a Hospital Emergency Department Testing Site. Diagnostics, 2021. 11(7). 118. Merino-Amador, P., et al., Multicenter evaluation of the Panbio™ COVID-19 Rapid Antigen- Detection Test for the diagnosis of SARS-CoV-2 infection. Clinical Microbiology and Infection, 2020. 27(5); p. 758-761. 119. Merino-Amador, P., et al., Multicenter evaluation	844	108.	Lee, J., et al., Clinical Performance of the Standard Q COVID-19 Rapid Antigen Test and
 41(6): p. 588-592. Leixner, G., et al., Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting. International Journal of Infectious Diseases, 2021. 108: p. 353-356. 110. Leli, C., et al., Performance of a SARS CoV-2 antigen rapid immunoassay in patients admitted to the Emergency Department. International Journal of Infectious Diseases, 2021. 110: p. 135-140. Linares, M., et al., Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms. Journal of Clinical Virology, 2020. 133: p. 104659. Lindner, A., et al., Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with professional-collected nasal versus nasopharyngeal swab. European Respiratory Journal, 2020. 57(5): p. 2004430. Lindner, A.K., et al., Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal versus professional-collected nasopharyngeal swab. European Respiratory Journal, 2021. 57(4). Lindner, A.K., et al., Diagnostic accuracy and feasibility of patient self-testing with a SARS- CoV-2 antigen-detecting rapid test. Journal of Clinical Virology, 2020. 202. 27: p. 487-488. Liotti, F.M., et al., Performance of a novel diagnostic assy for rapid SARS-CoV-2 in nasopharyngeal samples. medRxiv [Preprint]: published July 16, 2021. Menchinelli, G., et al., SARS-CoV-2 Antigen Detection to Expand Testing Site. Diagnostics, 2021. 11(7). Merino-Amador, P., et al., Clinitest rapid COVID-19 antigen test for the diagnosis of SARS- CoV-2 infection: A multicenter evaluation study. Journal of Clinical Virology, 2021. 143: p. 104961. Merino-Amador, P., et al., Multicenter evaluation of the PanbioTM COVID-19 Rapid Antigen- Detection Test for the diagnosis of SARS-CoV-2 infection. Clinical Microbiology and Infection, 2020. 27(5): p. 758-761. Mertens, P., et al., Development and Potential Use	845		Simulation of its Real-World Application in Korea. Annals of Laboratory Medicine, 2021.
 Leixner, G., et al., Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting. International Journal of Infectious Diseases, 2021. 108: p. 353-356. Leli, C., et al., Performance of a SARS CoV-2 antigen rapid immunoassay in patients admitted to the Emergency Department. International Journal of Infectious Diseases, 2021. 110: p. 135–140. Linares, M., et al., Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms. Journal of Clinical Virology, 2020. 133: p. 104659. Lindner, A., et al., Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with professional-collected nasal versus nasopharyngeal swab. European Respiratory Journal, 2020. 57(5): p. 2004430. Lindner, A.K., et al., Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal versus professional-collected nasopharyngeal swab. European Respiratory Journal, 2021. 57(4). Lindner, A.K., et al., Diagnostic accuracy and feasibility of patient self-testing with a SARS- CoV-2 antigen-detecting rapid test. Journal of Clinical Virology, 2021. 141: p. 104874. Lindner, A.K., et al., Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen detection in nasopharynx samples. Clinical Microbiology and Infection, 2020. 27: p. 487–488. Lunca, C., et al., Performance of antopen Ceptartent Testing Site. Diagnostics, 2021. 11(7). Merino-Amador, P., et al., Clinitest rapid COVID-19 antigen test for the diagnosis of SARS- CoV-2 infection: A multicenter evaluation study. Journal of Clinical Virology, 2021. 143: p. 104961. Merino-Amador, P., et al., Clinitest rapid COVID-19 antigen test for the diagnosis of SARS- CoV-2 infection: A multicenter evaluation of the Panbio™ COVID-19 Rapid Antigen- Detection Test for the diagnosis of SARS-CoV-2 infection. Clinical Microbiology and Infection, 2020. 27(5): p. 758-761.<td>846</td><td></td><td>41(6): p. 588-592.</td>	846		41 (6): p. 588-592.
 International Journal of Infectious Diseases, 2021. 108: p. 353-356. Leli, C., et al., <i>Performance of a SARS CoV-2 antigen rapid immunoassay in patients admitted</i> to the Emergency Department. International Journal of Infectious Diseases, 2021. 110: p. 135-140. Linares, M., et al., <i>Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in</i> the first 7 days after the onset of symptoms. Journal of Clinical Virology, 2020. 133: p. 104659. Lindner, A., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with</i> <i>professional-collected nasal versus nasopharyngeal swab</i>. European Respiratory Journal, 2020. 57(5): p. 2004430. Lindner, A.K., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test</i> <i>with self-collected nasal wersus professional-collected nasopharyngeal swab</i>. European Respiratory Journal, 2021. 57(4). Lindner, A.K., et al., <i>Diagnostic accuracy and feasibility of patient self-testing with a SARS- CoV-2 antigen-detecting rapid test</i>. Journal of Clinical Virology, 2021. 141: p. 104874. Lindtr, F.M., et al., <i>Performance of a novel diagnostic asay for rapid SARS-CoV-2 antigen</i> <i>detection in nasopharynx samples</i>. Clinical Microbiology and Infection, 2020. 27: p. 487–488. Linca, C., et al., <i>Performance of antigene detection of SARS-CoV-2 in nasopharyngeal</i> <i>samples</i>. medRxiv [Preprint]; published July 16, 2021. Merino-Amador, P., et al., <i>Clinitest rapid COVID-19 antigen test for the diagnosis of SARS- CoV-2 infection: A multicenter evaluation study</i>. Journal of Clinical Virology, 2021. 143; p. 104961. Merino-Amador, P., et al., <i>Multicenter evaluation of the Panbio™ COVID-19 Agi Respi-Strip</i> <i>Diagnostic Assay in a Pandemic Context</i>. Frontiers in Medicine, 2020. 7: p. 225. Mertens, P., et al., <i>Development and Potential Usefulness of the COVID-19 Ag Respi-Strip</i> <i>Diagnostic Assay in a Pandemic Context</i>. Fron	847	109.	Leixner, G., et al., Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting.
 Leli, C., et al., <i>Performance of a SARS CoV-2 antigen rapid immunoassay in patients admitted</i> to the Emergency Department. International Journal of Infectious Diseases, 2021. 110: p. 135–140. Linares, M., et al., <i>Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in</i> the first 7 days after the onset of symptoms. Journal of Clinical Virology, 2020. 133: p. 104659. Lindner, A., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with</i> professional-collected nasal versus nasopharyngeal swab. European Respiratory Journal, 2020. 57(5): p. 2004430. Lindner, A.K., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test</i> with self-collected nasal wersus professional-collected nasopharyngeal swab. European Respiratory Journal, 2021. 57(4). Lindner, A.K., et al., <i>Diagnostic accuracy and feasibility of patient self-testing with a SARS- CoV-2 antigen-detecting rapid test</i>. Journal of Clinical Virology, 2021. 141: p. 104874. Liotti, F.M., et al., <i>Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen</i> detection in nasopharynx samples. Clinical Microbiology and Infection, 2020. 27: p. 487–488. Luca, C., et al., <i>Performance of antigenic detection to Expand Testing Capacity for COVID-</i> 19: Results from a Hospital Emergency Department Testing Site. Diagnostics, 2021. 11(7). Merino-Amador, P., et al., <i>Clinitest rapid COVID-19 antigen test for the diagnosis of SARS- CoV-2 infection: A multicenter evaluation study</i>. Journal of Clinical Microbiology and Infection, 2020. 27(5): p. 758-761. Merino-Amador, P., et al., <i>Multicenter evaluation of the Panbio[™] COVID-19 Ag Respi-Strip</i> <i>Diagnostic Assay in a Pandemic Context</i>. Frontiers in Medicine, 2020. 7: p. 225. Micocci, M., et al., <i>Perint of Care Testing using rapid automated Antigen Testing for SARS- COV-2 in Care Homes – an exploratory sofety, usability and diagnostic agreement evaluation.</i> medRavig Uprenrin	848		International Journal of Infectious Diseases, 2021. 108: p. 353-356.
 to the Emergency Department. International Journal of Infectious Diseases, 2021. 110: p. 135–140. 111. Linares, M., et al., Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms. Journal of Clinical Virology, 2020. 133: p. 104659. 112. Lindner, A., et al., Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with professional-collected nasal versus nasopharyngeal swab. European Respiratory Journal, 2020. 57(5): p. 2004430. 113. Lindner, A.K., et al., Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal versus professional-collected nasopharyngeal swab. European Respiratory Journal, 2021. 57(4). 114. Lindner, A.K., et al., Diagnostic accuracy and feasibility of patient self-testing with a SARS-CoV-2 antigen-detecting rapid test. CoV-2 antigen-detecting rapid test. Journal of Clinical Virology, 2021. 141: p. 104874. 115. Liotti, F.M., et al., Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen detection in nasopharynx samples. Clinical Microbiology and Infection, 2020. 27: p. 487–488. 116. Lunca, C., et al., Performance of antigenic detection of SARS-CoV-2 in nasopharyngeal samples. medRxiv [Preprint]; published July 16, 2021. 117. Menchinelli, G., et al., SARS-CoV-2 Antigen Detection to Expand Testing Capacity for COVID-19: Results from a Hospital Emergency Department Testing Site. Diagnostics, 2021. 11(7). 118. Merino-Amador, P., et al., Multicenter evaluation of the Panbio[™] COVID-19 Rapid Antigen-Detection Test for the diagnosis of SARS-CoV-2 infection. 119. Merino-Amador, P., et al., Multicenter evaluation of the Panbio[™] COVID-19 Rapid Antigen-Detection Test for the diagnosis of SARS-CoV-2 infection. 119. Merino-Amador, P., et al., Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic C	849	110.	Leli, C., et al., Performance of a SARS CoV-2 antigen rapid immunoassay in patients admitted
 135–140. 111. Linares, M., et al., <i>Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms</i>. Journal of Clinical Virology, 2020. 133: p. 104659. 112. Lindner, A., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with professional-collected nasal versus nasopharyngeal swab</i>. European Respiratory Journal, 2020. 57(5): p. 2004430. 113. Lindner, A.K., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal wersus professional-collected nasopharyngeal swab</i>. European Respiratory Journal, 2020. 57(5): p. 2004430. 113. Lindner, A.K., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab versus professional-collected nasopharyngeal swab</i>. European Respiratory Journal, 2021. 57(4). 114. Lindner, A.K., et al., <i>Diagnostic accuracy and feasibility of patient self-testing with a SARS-CoV-2 antigen-detecting rapid test</i>. Journal of Clinical Virology, 2021. 141: p. 104874. 115. Liotti, F.M., et al., <i>Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen detection in nasopharyns samples</i>. Clinical Microbiology and Infection, 2020. 27: p. 487–488. 116. Lunca, C., et al., <i>Performance of antigenic detection of SARS-CoV-2 in nasopharyngeal samples</i>. medRxiv [Preprint]; published July 16, 2021. 117. Menchinelli, G., et al., <i>SARS-CoV-2 Antigen Detection to Expand Testing Capacity for COVID-19 : Results from a Hospital Emergency Department Testing Ste. Diagnostics</i>, 2021. 11(7). 118. Merino-Amador, P., et al., <i>Clinitest rapid COVID-19 antigen test for the diagnosis of SARS-COV-2 infection: A multicenter evaluation study</i>. Journal of Clinical Virology, 2021. 143: p. 104961. 119. Merino-Amador, P., et al., <i>Multicenter evaluation of the PanbioTM COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context</i>. Frontiers in Medicine,	850		to the Emergency Department. International Journal of Infectious Diseases, 2021. 110: p.
 Linares, M., et al., Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms. Journal of Clinical Virology, 2020. 133: p. 104659. Lindner, A., et al., Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with professional-collected nasal versus nasopharyngeal swab. European Respiratory Journal, 2020. 57(5): p. 2004430. Lindner, A.K., et al., Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab versus professional-collected nasopharyngeal swab. European Respiratory Journal, 2021. 57(4). Lindner, A.K., et al., Diagnostic accuracy and feasibility of patient self-testing with a SARS- CoV-2 antigen-detecting rapid test. Journal of Clinical Virology, 2021. 141: p. 104874. Liotti, F.M., et al., Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen detection in nasopharynx samples. Clinical Microbiology and Infection, 2020. 27: p. 487–488. Lunca, C., et al., Performance of antigenic detection of SARS-CoV-2 in nasopharyngeal samples. medRxiv [Preprint]; published July 16, 2021. Menchnelli, G., et al., SARS-CoV-2 Antigen Detection to Expand Testing Capacity for COVID- 19: Results from a Hospital Emergency Department Testing Site. Diagnostic, 2021. 143: p. 104961. Merino-Amador, P., et al., Multicenter evaluation of the PanbioTM COVID-19 Rapid Antigen- Detection Test for the diagnosis of SARS-CoV-2 infection. Clinical Microbiology and Infection, 2020. 27(5): p. 758-761. Mertens, P., et al., Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context. Frontiers in Medicine, 2020. 7: p. 225. Micocci, M., et al., Point of Care Testing using rapid automated Antigen Testing for SARS- CoV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation. medRxiv [Preprint]: published April 26. 2021 	851		135–140.
 the first 7 days after the onset of symptoms. Journal of Clinical Virology, 2020. 133: p. 104659. Lindner, A., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with professional-collected nasal versus nasopharyngeal swab.</i> European Respiratory Journal, 2020. 57(5): p. 2004430. Lindner, A.K., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab versus professional-collected nasopharyngeal swab.</i> European Respiratory Journal, 2021. 57(4). Lindner, A.K., et al., <i>Diagnostic accuracy and feasibility of patient self-testing with a SARS-CoV-2 antigen-detecting rapid test. CoV-2 antigen-detecting rapid test. CoV-2 antigen-detecting rapid test. Journal of Clinical Virology, 2021. 141: p. 104874.</i> Liotti, F.M., et al., <i>Performance of a novel diagnostic assy for rapid SARS-CoV-2 antigen detection in nasopharynx samples.</i> Clinical Microbiology and Infection, 2020. 27: p. 487–488. Lunca, C., et al., <i>Performance of antigenic detection of SARS-CoV-2 in nasopharyngeal samples.</i> medRxiv [Preprint]; published July 16, 2021. Menchinelli, G., et al., <i>SARS-CoV-2 Antigen Detection to Expand Testing Capacity for COVID-19: Results from a Hospital Emergency Department Testing Site.</i> Diagnostics, 2021. 11(7). Merino-Amador, P., et al., <i>Clinitest rapid COVID-19 antigen test for the diagnosis of SARS-COV-2 infection: A multicenter evaluation study.</i> Journal of Clinical Microbiology and Infection, 2020. 27(5): p. 758-761. Mertens, P., et al., <i>Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context.</i> Frontiers in Medicine, 2020. 7: p. 225. Micoci, M., et al., <i>Point of Care Testing using rapid automated Antigen Testing for SARS-COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation.</i> medRyi (Preprint): published April 26, 2021 	852	111.	Linares, M., et al., Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in
 104659. Lindner, A., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with</i> <i>professional-collected nasal versus nasopharyngeal swab.</i> European Respiratory Journal, 2020. 57(5): p. 2004430. Lindner, A.K., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test</i> <i>with self-collected nasal swab versus professional-collected nasopharyngeal swab.</i> European Respiratory Journal, 2021. 57(4). Lindner, A.K., et al., <i>Diagnostic accuracy and feasibility of patient self-testing with a SARS- CoV-2 antigen-detecting rapid test.</i> Journal of Clinical Virology, 2021. 141: p. 104874. Liotti, F.M., et al., <i>Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen</i> <i>detection in nasopharynx samples.</i> Clinical Microbiology and Infection, 2020. 27: p. 487–488. Lunca, C., et al., <i>Performance of antigenic detection of SARS-CoV-2 in nasopharyngeal</i> <i>samples.</i> medRxiv [Preprint]; published July 16, 2021. Mernino-Amador, P., et al., <i>Clinitest rapid COVID-19 antigen test for the diagnosis of SARS- CoV-2 infection: A multicenter evaluation study.</i> Journal of Clinical Virology, 2021. 143: p. 104961. Merino-Amador, P., et al., <i>Multicenter evaluation of the Panbio™ COVID-19 Rapid Antigen</i> <i>Detection Test for the diagnosis of SARS-CoV-2 infection.</i> Clinical Microbiology and Infection, 2020. 27(5): p. 758-761. Mertens, P., et al., <i>Development and Potential Usefulness of the COVID-19 Ag Respi-Strip</i> <i>Diagnostic Assay in a Pandemic Context.</i> Frontiers in Medicine, 2020. 7: p. 225. Micocci, M., et al., <i>Development and Potential Usefulness of the COVID-19 Ag Respi-Strip</i> <i>Diagnostic Assay in a Pandemic Context.</i> Frontiers in Medicine, 2020. 7: p. 225. Micocci, M., et al., <i>Doint of Care Testing using rapid automated Antigen Testing for SARS-COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation.</i> <i>Reversin Previntl:</i> published April 26, 2021 <td>853</td><td></td><td>the first 7 days after the onset of symptoms. Journal of Clinical Virology, 2020. 133: p.</td>	853		the first 7 days after the onset of symptoms. Journal of Clinical Virology, 2020. 133: p.
 Lindner, A., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with</i> <i>professional-collected nasal versus nasopharyngeal swab.</i> European Respiratory Journal, 2020. 57(5): p. 2004430. Lindner, A.K., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test</i> <i>with self-collected nasal swab versus professional-collected nasopharyngeal swab.</i> European Respiratory Journal, 2021. 57(4). Lindner, A.K., et al., <i>Diagnostic accuracy and feasibility of patient self-testing with a SARS- CoV-2 antigen-detecting rapid test.</i> Journal of Clinical Virology, 2021. 141: p. 104874. Liotti, F.M., et al., <i>Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen</i> <i>detection in nasopharynx samples.</i> Clinical Microbiology and Infection, 2020. 27: p. 487–488. Lunca, C., et al., <i>Performance of antigenic detection of SARS-CoV-2 in nasopharyngeal</i> <i>samples.</i> medRxiv [Preprint]; published July 16, 2021. Menchinelli, G., et al., <i>SARS-CoV-2 Antigen Detection to Expand Testing Capacity for COVID-</i> <i>19: Results from a Hospital Emergency Department Testing Site.</i> Diagnostics, 2021. 11(7). Merino-Amador, P., et al., <i>Multicenter evaluation study.</i> Journal of Clinical Virology, 2021. 143: p. 104961. Merino-Amador, P., et al., <i>Multicenter evaluation of the PanbioTM COVID-19 Rapid Antigen-</i> <i>Detection Test for the diagnosis of SARS-CoV-2 infection.</i> Clinical Microbiology and Infection, 2020. 27(5): p. 758-761. Mertens, P., et al., <i>Development and Potential Usefulness of the COVID-19 Ag Respi-Strip</i> <i>Diagnostic Assay in a Pandemic Context.</i> Frontiers in Medicine, 2020. 7: p. 225. Micocci, M., et al., <i>Point of Care Testing using rapid automated Antigen Testing for SARS-</i> <i>COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation.</i> medRxiv [Preprint]: published April 26. 2021 	854		104659.
 professional-collected nasal versus nasopharyngeal swab. European Respiratory Journal, 2020. 57(5): p. 2004430. 113. Lindner, A.K., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test</i> with self-collected nasal swab versus professional-collected nasopharyngeal swab. European Respiratory Journal, 2021. 57(4). 114. Lindner, A.K., et al., <i>Diagnostic accuracy and feasibility of patient self-testing with a SARS-CoV-2 antigen-detecting rapid test</i>. Journal of Clinical Virology, 2021. 141: p. 104874. 115. Liotti, F.M., et al., <i>Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen detection in nasopharynx samples</i>. Clinical Microbiology and Infection, 2020. 27: p. 487–488. 116. Lunca, C., et al., <i>Performance of antigenic detection to Expand Testing Capacity for COVID-19 results from a Hospital Emergency Department Testing Site</i>. Diagnostics, 2021. 11(7). 118. Merino-Amador, P., et al., <i>Colitet revaluation study</i>. Journal of Clinical Virology, 2021. 143: p. 104961. 119. Merino-Amador, P., et al., <i>Multicenter evaluation of the Panbio™ COVID-19 Rapid Antigen-Detection Test for the diagnosis of SARS-CoV-2 infection</i>. Clinical Microbiology and Infection, 2020. 27(5): p. 758-761. 120. Mertens, P., et al., <i>Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context</i>. Frontiers in Medicine, 2020. 7: p. 225. 121. Micocci, M., et al., <i>Point of Care Testing using rapid automated Antigen Testing for SARS-COV-2 in Cov-2 in Care Testing using rapid automated Antigen Testing for SARS-COV-2 in Care Testing using rapid automated Antigen Testing for SARS-COV-2 in Cov-2 in Care Testing using rapid automated Antigen Testing for SARS-COV-2 in Care Testing using rapid automated Antigen Testing for SARS-COV-2 in Care Testing using rapid automated Antigen Testing for SARS-COV-2 in Care Testing using rapid automated Antigen Testing for SARS-COV-</i>	855	112.	Lindner, A., et al., Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with
 2020. 57(5): p. 200430. 113. Lindner, A.K., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test</i> <i>with self-collected nasal swab versus professional-collected nasopharyngeal swab</i>. European Respiratory Journal, 2021. 57(4). 114. Lindner, A.K., et al., <i>Diagnostic accuracy and feasibility of patient self-testing with a SARS-CoV-2 antigen-detecting rapid test</i>. Journal of Clinical Virology, 2021. 141: p. 104874. 115. Liotti, F.M., et al., <i>Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen</i> <i>detection in nasopharynx samples</i>. Clinical Microbiology and Infection, 2020. 27: p. 487–488. 116. Lunca, C., et al., <i>Performance of antigenic detection of SARS-CoV-2 in nasopharyngeal</i> <i>samples</i>. medRxiv [Preprint]; published July 16, 2021. 117. Menchinelli, G., et al., <i>SARS-CoV-2 Antigen Detection to Expand Testing Capacity for COVID-</i> <i>19: Results from a Hospital Emergency Department Testing Site</i>. Diagnostics, 2021. 11(7). 118. Merino-Amador, P., et al., <i>Clinitest rapid COVID-19 antigen test for the diagnosis of SARS-</i> <i>CoV-2 infection: A multicenter evaluation study</i>. Journal of Clinical Virology, 2021. 143: p. 104961. 119. Merino-Amador, P., et al., <i>Multicenter evaluation of the Panbio™ COVID-19 Rapid Antigen-</i> <i>Detection Test for the diagnosis of SARS-CoV-2 infection</i>. Clinical Microbiology and Infection, 2020. 27(5): p. 758-761. 120. Mertens, P., et al., <i>Development and Potential Usefulness of the COVID-19 Ag Respi-Strip</i> <i>Diagnostic Assay in a Pandemic Context</i>. Frontiers in Medicine, 2020. 7: p. 225. 121. Micocci, M., et al., <i>Point of Care Testing using rapid automated Antigen Testing for SARS-</i> <i>COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation.</i> medRxiv [Preprint]. 	856		professional-collected nasal versus nasopharyngeal swab. European Respiratory Journal,
 Lindner, A.K., et al., <i>Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test</i> with self-collected nasal swab versus professional-collected nasopharyngeal swab. European Respiratory Journal, 2021. 57(4). Lindner, A.K., et al., <i>Diagnostic accuracy and feasibility of patient self-testing with a SARS- CoV-2 antigen-detecting rapid test</i>. Journal of Clinical Virology, 2021. 141: p. 104874. Liotti, F.M., et al., <i>Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen</i> <i>detection in nasopharynx samples</i>. Clinical Microbiology and Infection, 2020. 27: p. 487–488. Lunca, C., et al., <i>Performance of antigenic detection of SARS-CoV-2 in nasopharyngeal</i> <i>samples</i>. medRxiv [Preprint]; published July 16, 2021. Menchinelli, G., et al., <i>SARS-CoV-2 Antigen Detection to Expand Testing Capacity for COVID-</i> <i>19: Results from a Hospital Emergency Department Testing Site</i>. Diagnostics, 2021. 11(7). Merino-Amador, P., et al., <i>Multicenter evaluation study</i>. Journal of Clinical Virology, 2021. 143: p. 104961. Merino-Amador, P., et al., <i>Multicenter evaluation of the Panbio™ COVID-19 Rapid Antigen</i> <i>Detection Test for the diagnosis of SARS-CoV-2 infection</i>. Clinical Microbiology and Infection, 2020. 27(5): p. 758-761. Mertens, P., et al., <i>Development and Potential Usefulness of the COVID-19 Ag Respi-Strip</i> <i>Diagnostic Assay in a Pandemic Context</i>. Frontiers in Medicine, 2020. 7: p. 225. Micocci, M., et al., <i>Point of Care Testing using rapid automated Antigen Testing for SARS- COV-2 in care Homes – an exploratory safety, usability and diagnostic agreement evaluation</i>. 	857		2020. 57 (5): p. 2004430.
 with self-collected nasal swab versus professional-collected nasopharyngeal swab. European Respiratory Journal, 2021. 57(4). 114. Lindner, A.K., et al., Diagnostic accuracy and feasibility of patient self-testing with a SARS- CoV-2 antigen-detecting rapid test. Journal of Clinical Virology, 2021. 141: p. 104874. 115. Liotti, F.M., et al., Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen detection in nasopharynx samples. Clinical Microbiology and Infection, 2020. 27: p. 487–488. 116. Lunca, C., et al., Performance of antigenic detection of SARS-CoV-2 in nasopharyngeal samples. medRxiv [Preprint]; published July 16, 2021. 117. Menchinelli, G., et al., SARS-CoV-2 Antigen Detection to Expand Testing Capacity for COVID- 19: Results from a Hospital Emergency Department Testing Site. Diagnostics, 2021. 11(7). 118. Merino-Amador, P., et al., Clinitest rapid COVID-19 antigen test for the diagnosis of SARS- CoV-2 infection: A multicenter evaluation study. Journal of Clinical Virology, 2021. 143: p. 104961. 119. Merino-Amador, P., et al., Multicenter evaluation of the Panbio™ COVID-19 Rapid Antigen- Detection Test for the diagnosis of SARS-CoV-2 infection. Clinical Microbiology and Infection, 2020. 27(5): p. 758-761. 120. Mertens, P., et al., Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context. Frontiers in Medicine, 2020. 7: p. 225. 121. Micocci, M., et al., Point of Care Testing using rapid automated Antigen Testing for SARS- COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation. medRxiv [Preprint]: published Anril 26. 2021 	858	113.	Lindner, A.K., et al., Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test
 Respiratory Journal, 2021. 57(4). Lindner, A.K., et al., <i>Diagnostic accuracy and feasibility of patient self-testing with a SARS-CoV-2 antigen-detecting rapid test</i>. Journal of Clinical Virology, 2021. 141: p. 104874. Liotti, F.M., et al., <i>Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen detection in nasopharynx samples</i>. Clinical Microbiology and Infection, 2020. 27: p. 487–488. Lunca, C., et al., <i>Performance of antigenic detection of SARS-CoV-2 in nasopharyngeal samples</i>. medRxiv [Preprint]; published July 16, 2021. Menchinelli, G., et al., <i>SARS-CoV-2 Antigen Detection to Expand Testing Capacity for COVID-19: Results from a Hospital Emergency Department Testing Site</i>. Diagnostics, 2021. 11(7). Merino-Amador, P., et al., <i>Clinitest rapid COVID-19 antigen test for the diagnosis of SARS-CoV-2 infection: A multicenter evaluation study</i>. Journal of Clinical Virology, 2021. 143: p. 104961. Merino-Amador, P., et al., <i>Multicenter evaluation of the Panbio™ COVID-19 Rapid Antigen-Detection Test for the diagnosis of SARS-CoV-2 (SARS-CoV-2 (SARS-COV-2))</i>. Mertens, P., et al., <i>Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context</i>. Frontiers in Medicine, 2020. 7: p. 225. Miccoci, M., et al., <i>Point of Care Testing using rapid automated Antigen Testing for SARS-COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation</i>. 	859		with self-collected nasal swab versus professional-collected nasopharyngeal swab. European
 114. Lindner, A.K., et al., <i>Diagnostic accuracy and feasibility of patient self-testing with a SARS-CoV-2 antigen-detecting rapid test</i>. Journal of Clinical Virology, 2021. 141: p. 104874. 115. Liotti, F.M., et al., <i>Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen detection in nasopharynx samples</i>. Clinical Microbiology and Infection, 2020. 27: p. 487–488. 116. Lunca, C., et al., <i>Performance of antigenic detection of SARS-CoV-2 in nasopharyngeal samples</i>. medRxiv [Preprint]; published July 16, 2021. 117. Menchinelli, G., et al., <i>SARS-CoV-2 Antigen Detection to Expand Testing Capacity for COVID-19: Results from a Hospital Emergency Department Testing Site</i>. Diagnostics, 2021. 11(7). 118. Merino-Amador, P., et al., <i>Clinitest rapid COVID-19 antigen test for the diagnosis of SARS-CoV-2 infection: A multicenter evaluation study</i>. Journal of Clinical Virology, 2021. 143: p. 104961. 119. Merino-Amador, P., et al., <i>Multicenter evaluation of the Panbio™ COVID-19 Rapid Antigen-Detection Test for the diagnosis of SARS-CoV-2 infection</i>. Clinical Microbiology and Infection, 2020. 27(5): p. 758-761. 120. Mertens, P., et al., <i>Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context</i>. Frontiers in Medicine, 2020. 7: p. 225. 121. Micocci, M., et al., <i>Point of Care Testing using rapid automated Antigen Testing for SARS-COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation. medRxiv [Preprint]: published Anril 26, 2021</i> 	860		Respiratory Journal, 2021. 57(4).
 <i>CoV-2 antigen-detecting rapid test.</i> Journal of Clinical Virology, 2021. 141: p. 104874. Liotti, F.M., et al., <i>Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen detection in nasopharynx samples.</i> Clinical Microbiology and Infection, 2020. 27: p. 487–488. Lunca, C., et al., <i>Performance of antigenic detection of SARS-CoV-2 in nasopharyngeal samples.</i> medRxiv [Preprint]; published July 16, 2021. Menchinelli, G., et al., <i>SARS-CoV-2 Antigen Detection to Expand Testing Capacity for COVID-19: Results from a Hospital Emergency Department Testing Site.</i> Diagnostics, 2021. 11(7). Merino-Amador, P., et al., <i>Clinitest rapid COVID-19 antigen test for the diagnosis of SARS-CoV-2 infection: A multicenter evaluation study.</i> Journal of Clinical Virology, 2021. 143: p. 104961. Merino-Amador, P., et al., <i>Multicenter evaluation of the Panbio™ COVID-19 Rapid Antigen-Detection Test for the diagnosis of SARS-CoV-2 infection.</i> Clinical Microbiology and Infection, 2020. 27(5): p. 758-761. Mertens, P., et al., <i>Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context.</i> Frontiers in Medicine, 2020. 7: p. 225. Micocci, M., et al., <i>Point of Care Testing using rapid automated Antigen Testing for SARS-COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation.</i> medRxiv [Preprint]: published April 26. 2021 	861	114.	Lindner, A.K., et al., Diagnostic accuracy and feasibility of patient self-testing with a SARS-
 Liotti, F.M., et al., <i>Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen</i> <i>detection in nasopharynx samples.</i> Clinical Microbiology and Infection, 2020. 27: p. 487–488. Lunca, C., et al., <i>Performance of antigenic detection of SARS-CoV-2 in nasopharyngeal</i> <i>samples.</i> medRxiv [Preprint]; published July 16, 2021. Menchinelli, G., et al., <i>SARS-CoV-2 Antigen Detection to Expand Testing Capacity for COVID-</i> <i>19: Results from a Hospital Emergency Department Testing Site.</i> Diagnostics, 2021. 11(7). Merino-Amador, P., et al., <i>Clinitest rapid COVID-19 antigen test for the diagnosis of SARS-</i> <i>CoV-2 infection: A multicenter evaluation study.</i> Journal of Clinical Virology, 2021. 143: p. 104961. Merino-Amador, P., et al., <i>Multicenter evaluation of the Panbio™ COVID-19 Rapid Antigen-</i> <i>Detection Test for the diagnosis of SARS-CoV-2 infection.</i> Clinical Microbiology and Infection, 2020. 27(5): p. 758-761. Mertens, P., et al., <i>Development and Potential Usefulness of the COVID-19 Ag Respi-Strip</i> <i>Diagnostic Assay in a Pandemic Context.</i> Frontiers in Medicine, 2020. 7: p. 225. Micocci, M., et al., <i>Point of Care Testing using rapid automated Antigen Testing for SARS-</i> <i>COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation.</i> medRxiv [Preprint]: published April 26, 2021 	862		<i>CoV-2 antigen-detecting rapid test.</i> Journal of Clinical Virology, 2021. 141 : p. 104874.
 detection in nasopharynx samples. Clinical Microbiology and Infection, 2020. 27: p. 487–488. Lunca, C., et al., Performance of antigenic detection of SARS-CoV-2 in nasopharyngeal samples. medRxiv [Preprint]; published July 16, 2021. Menchinelli, G., et al., SARS-CoV-2 Antigen Detection to Expand Testing Capacity for COVID- 19: Results from a Hospital Emergency Department Testing Site. Diagnostics, 2021. 11(7). Merino-Amador, P., et al., Clinitest rapid COVID-19 antigen test for the diagnosis of SARS- CoV-2 infection: A multicenter evaluation study. Journal of Clinical Virology, 2021. 143: p. 104961. Merino-Amador, P., et al., Multicenter evaluation of the Panbio[™] COVID-19 Rapid Antigen- Detection Test for the diagnosis of SARS-CoV-2 infection. Clinical Microbiology and Infection, 2020. 27(5): p. 758-761. Mertens, P., et al., Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context. Frontiers in Medicine, 2020. 7: p. 225. Micocci, M., et al., Point of Care Testing using rapid automated Antigen Testing for SARS- COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation. medRxiv [Preprint]: published April 26, 2021 	863	115.	Liotti, F.M., et al., Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen
 Lunca, C., et al., <i>Performance of antigenic detection of SARS-CoV-2 in nasopharyngeal</i> <i>samples.</i> medRxiv [Preprint]; published July 16, 2021. Menchinelli, G., et al., <i>SARS-CoV-2 Antigen Detection to Expand Testing Capacity for COVID-</i> <i>19: Results from a Hospital Emergency Department Testing Site.</i> Diagnostics, 2021. 11(7). Merino-Amador, P., et al., <i>Clinitest rapid COVID-19 antigen test for the diagnosis of SARS-</i> <i>CoV-2 infection: A multicenter evaluation study.</i> Journal of Clinical Virology, 2021. 143: p. 104961. Merino-Amador, P., et al., <i>Multicenter evaluation of the Panbio™ COVID-19 Rapid Antigen-</i> <i>Detection Test for the diagnosis of SARS-CoV-2 infection.</i> Clinical Microbiology and Infection, 2020. 27(5): p. 758-761. Mertens, P., et al., <i>Development and Potential Usefulness of the COVID-19 Ag Respi-Strip</i> <i>Diagnostic Assay in a Pandemic Context.</i> Frontiers in Medicine, 2020. 7: p. 225. Micocci, M., et al., <i>Point of Care Testing using rapid automated Antigen Testing for SARS-</i> <i>COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation.</i> medRxiv [Preprint]: published April 26, 2021 	864		detection in nasopharynx samples. Clinical Microbiology and Infection, 2020. 27: p. 487–488.
 samples. medRxiv [Preprint]; published July 16, 2021. Menchinelli, G., et al., SARS-CoV-2 Antigen Detection to Expand Testing Capacity for COVID- 19: Results from a Hospital Emergency Department Testing Site. Diagnostics, 2021. 11(7). Merino-Amador, P., et al., Clinitest rapid COVID-19 antigen test for the diagnosis of SARS- CoV-2 infection: A multicenter evaluation study. Journal of Clinical Virology, 2021. 143: p. 104961. Merino-Amador, P., et al., Multicenter evaluation of the Panbio[™] COVID-19 Rapid Antigen- Detection Test for the diagnosis of SARS-CoV-2 infection. Clinical Microbiology and Infection, 2020. 27(5): p. 758-761. Mertens, P., et al., Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context. Frontiers in Medicine, 2020. 7: p. 225. Micocci, M., et al., Point of Care Testing using rapid automated Antigen Testing for SARS- COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation. medRxiv [Preprint]: published April 26, 2021 	865	116.	Lunca, C., et al., Performance of antigenic detection of SARS-CoV-2 in nasopharynaeal
 Menchinelli, G., et al., SARS-CoV-2 Antigen Detection to Expand Testing Capacity for COVID- 19: Results from a Hospital Emergency Department Testing Site. Diagnostics, 2021. 11(7). Merino-Amador, P., et al., Clinitest rapid COVID-19 antigen test for the diagnosis of SARS- CoV-2 infection: A multicenter evaluation study. Journal of Clinical Virology, 2021. 143: p. 104961. Merino-Amador, P., et al., Multicenter evaluation of the Panbio™ COVID-19 Rapid Antigen- Detection Test for the diagnosis of SARS-CoV-2 infection. Clinical Microbiology and Infection, 2020. 27(5): p. 758-761. Mertens, P., et al., Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context. Frontiers in Medicine, 2020. 7: p. 225. Micocci, M., et al., Point of Care Testing using rapid automated Antigen Testing for SARS- COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation. medRxiv [Preprint]: published April 26, 2021 	866		samples. medRxiv [Preprint]: published July 16. 2021.
 19: Results from a Hospital Emergency Department Testing Site. Diagnostics, 2021. 11(7). 118. Merino-Amador, P., et al., Clinitest rapid COVID-19 antigen test for the diagnosis of SARS- CoV-2 infection: A multicenter evaluation study. Journal of Clinical Virology, 2021. 143: p. 104961. 119. Merino-Amador, P., et al., Multicenter evaluation of the Panbio™ COVID-19 Rapid Antigen- Detection Test for the diagnosis of SARS-CoV-2 infection. Clinical Microbiology and Infection, 2020. 27(5): p. 758-761. 120. Mertens, P., et al., Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context. Frontiers in Medicine, 2020. 7: p. 225. 121. Micocci, M., et al., Point of Care Testing using rapid automated Antigen Testing for SARS- COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation. 	867	117.	Menchinelli, G., et al., SARS-CoV-2 Antigen Detection to Expand Testing Capacity for COVID-
 Merino-Amador, P., et al., <i>Clinitest rapid COVID-19 antigen test for the diagnosis of SARS-</i> <i>CoV-2 infection: A multicenter evaluation study.</i> Journal of Clinical Virology, 2021. 143: p. 104961. Merino-Amador, P., et al., <i>Multicenter evaluation of the Panbio™ COVID-19 Rapid Antigen-</i> <i>Detection Test for the diagnosis of SARS-CoV-2 infection.</i> Clinical Microbiology and Infection, 2020. 27(5): p. 758-761. Mertens, P., et al., <i>Development and Potential Usefulness of the COVID-19 Ag Respi-Strip</i> <i>Diagnostic Assay in a Pandemic Context.</i> Frontiers in Medicine, 2020. 7: p. 225. Micocci, M., et al., <i>Point of Care Testing using rapid automated Antigen Testing for SARS-</i> <i>COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation.</i> medRxiv [Preprint]: published April 26, 2021 	868		19: Results from a Hospital Emergency Department Testing Site. Diagnostics, 2021, 11 (7).
 CoV-2 infection: A multicenter evaluation study. Journal of Clinical Virology, 2021. 143: p. 104961. Merino-Amador, P., et al., Multicenter evaluation of the Panbio[™] COVID-19 Rapid Antigen- Detection Test for the diagnosis of SARS-CoV-2 infection. Clinical Microbiology and Infection, 2020. 27(5): p. 758-761. Mertens, P., et al., Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context. Frontiers in Medicine, 2020. 7: p. 225. Micocci, M., et al., Point of Care Testing using rapid automated Antigen Testing for SARS- COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation. medRxiv [Preprint]: published April 26, 2021 	869	118	Merino-Amador, P., et al., Clinitest rapid COVID-19 antigen test for the diagnosis of SARS-
 104961. Merino-Amador, P., et al., Multicenter evaluation of the Panbio[™] COVID-19 Rapid Antigen- Detection Test for the diagnosis of SARS-CoV-2 infection. Clinical Microbiology and Infection, 2020. 27(5): p. 758-761. Mertens, P., et al., Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context. Frontiers in Medicine, 2020. 7: p. 225. Micocci, M., et al., Point of Care Testing using rapid automated Antigen Testing for SARS- COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation. medRxiv [Preprint]: published April 26, 2021 	870		CoV-2 infection: A multicenter evaluation study Journal of Clinical Virology 2021 143 : n
 Merino-Amador, P., et al., Multicenter evaluation of the Panbio[™] COVID-19 Rapid Antigen- Detection Test for the diagnosis of SARS-CoV-2 infection. Clinical Microbiology and Infection, 2020. 27(5): p. 758-761. Mertens, P., et al., Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context. Frontiers in Medicine, 2020. 7: p. 225. Micocci, M., et al., Point of Care Testing using rapid automated Antigen Testing for SARS- COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation. medRxiv [Preprint]: published April 26, 2021 	871		104961
872113.Micrinio Antidot, 1., et al., Multicenter evaluation of the Fundor Covid 15 hapid Antigen873Detection Test for the diagnosis of SARS-CoV-2 infection. Clinical Microbiology and Infection,8742020. 27(5): p. 758-761.875120.876Diagnostic Assay in a Pandemic Context. Frontiers in Medicine, 2020. 7: p. 225.877121.878COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation.879medRxiv [Preprint]: published April 26, 2021	872	119	Merino-Amador P et al Multicenter evaluation of the Panhio™ COVID-19 Rapid Antigen-
 Bit and the context for the undersology and intection. Chined intection, ended intection, 2020. 27(5): p. 758-761. Bit and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context. Frontiers in Medicine, 2020. 7: p. 225. Bit and the context of the covid and the covid	873	115.	Detection Test for the diagnosis of SARS-CoV-2 infection. Clinical Microbiology and Infection
 874 2020. 27(5): p. 758-701. 875 120. Mertens, P., et al., <i>Development and Potential Usefulness of the COVID-19 Ag Respi-Strip</i> 876 <i>Diagnostic Assay in a Pandemic Context</i>. Frontiers in Medicine, 2020. 7: p. 225. 877 121. Micocci, M., et al., <i>Point of Care Testing using rapid automated Antigen Testing for SARS-</i> 878 <i>COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation.</i> 879 medRxiv [Preprint]: published April 26, 2021 	874		2020 27 (5) n 758-761
 Mertens, F., et al., Development und Potential Osefaness of the COVD-19 Ag Respiration Diagnostic Assay in a Pandemic Context. Frontiers in Medicine, 2020. 7: p. 225. Micocci, M., et al., Point of Care Testing using rapid automated Antigen Testing for SARS- COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation. medRxiv [Preprint]: published April 26, 2021 	074 975	120	Martens P. et al. Development and Potential Lisefulness of the COVID-19 Ag Pesni-Strin
 Micocci, M., et al., Point of Care Testing using rapid automated Antigen Testing for SARS- COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation. medRxiv [Preprint]: published April 26, 2021 	876	120.	Diagnostic Assay in a Pandemic Context Frontiers in Medicine 2020 7. n 225
878 <i>COV-2 in Care Homes – an exploratory safety, usability and diagnostic agreement evaluation.</i> 879 medRxiv [Preprint]: published April 26, 2021	877	121	Microcci M et al Point of Care Testing using ranid automated Antigen Testing for SAPS-
879 medRxiv [Prenrint]: nublished Anril 26, 2021	878	121.	COV-2 in Care Homes – an exploratory safety usability and diagnostic agreement evaluation
	879		medRxiv [Preprint]: published April 26, 2021.

880	122.	Möckel, M., et al., SARS-CoV-2 Antigen Rapid Immunoassay for Diagnosis of COVID-19 in the
881		Emergency Department. Biomarkers, 2021. 26(3): p. 213-220.
882	123.	Muhi, S., et al., Multi-site assessment of rapid, point-of-care antigen testing for the diagnosis
883		of SARS-CoV-2 infection in a low-prevalence setting: A validation and implementation study.
884		Lancet Regional Health Western Pacific, 2021. 9 : p. 100115.
885	124.	Nalumansi, A., et al., Field Evaluation of the Performance of a SARS-CoV-2 Antigen Rapid
886		Diagnostic Test in Uganda using Nasopharyngeal Samples. International Journal of Infectious
887		Diseases, 2020. 104 : p. 282-286.
888	125.	Ngo Nsoga, M.T., et al., Diagnostic accuracy of Panbio rapid antigen tests on oropharyngeal
889		<i>swabs for detection of SARS-CoV-2.</i> PLoS ONE, 2021. 16 (6): p. e0253321.
890	126.	Nikolai, O., et al., Anterior nasal versus nasal mid-turbinate sampling for a SARS-CoV-2
891		antigen-detecting rapid test: does localisation or professional collection matter? Infectious
892		Diseases, 2021: p. 1-6.
893	127.	Nordgren, J., et al., SARS-CoV-2 rapid antigen test: High sensitivity to detect infectious virus.
894		Journal of Clinical Virology, 2021. 140 : p. 104846.
895	128.	Okoye, N.C., et al., Performance Characteristics of BinaxNOW COVID-19 Antigen Card for
896		Screening Asymptomatic Individuals in a University Setting. Journal of Clinical Microbiology,
897		2021. 59 (4): p. e03282-20.
898	129.	Onsongo, S.N., et al., Field performance of NowCheck rapid antigen test for SARS-CoV-2 in
899		Kisumu County, western Kenya. medRxiv [Preprint]; published August 13, 2021.
900	130.	Orsi, A., et al., On-field evaluation of a ultra-rapid fluorescence immunoassay as a frontline
901		test for SARS-COV-2 diagnostic. Journal of Virological Methods, 2021. 295 : p. 114201.
902	131.	Osmanodja, B., et al., Accuracy of a Novel SARS-CoV-2 Antigen-Detecting Rapid Diagnostic
903		Test from Standardized Self-Collected Anterior Nasal Swabs. Journal of Clinical Medicine,
904		2021. 10 (10).
905	132.	Osterman, A., et al., Evaluation of two rapid antigen tests to detect SARS-CoV-2 in a hospital
906		setting. Medical Microbiology and Immunology, 2021. 210 (1): p. 65-72.
907	133.	Osterman, A., et al., Comparison of four commercial, automated antigen tests to detect SARS-
908		CoV-2 variants of concern. Medical Microbiology and Immunology, 2021: p. 1-13.
909	134.	Parada-Ricart, E., et al., Usefulness of the antigen for diagnosing SARS-CoV-2 infection in
910		patients with and without symptoms. Enfermedades infecciosas y Microbiologia Clinica,
911	105	2020. 39 : p. 357-358.
912	135.	Pekosz, A., et al., Antigen-based testing but not real-time PCR correlates with SARS-CoV-2
913	100	Virus culture. Clinical infectious Diseases, 2020. Claal/06.
914	130.	Pena, M., et al., Perjormance of SARS-COV-2 rapid antigen test compared with real-time R1-
915		PCR in asymptomatic individuals. International Journal of Infectious Diseases, 2021. 107 : p.
916	107	201-204. Réserve Courtes Courtes and Reaching antigon reacid
917	137.	diagnostic tests to diagnose SARS CoV 2 infection Journal of Clinical Virology 2021 127 : n
910		104791
919	120	104/81. Derez Careia E. et al. Comparative evaluation of Panhie and CD Biosenser antigen ranid
920	150.	diagnostic tests for COVID 10 diagnosis Journal of Modical Virology 2021 02(0): p. EEEO
921		
922	120	Doto T COVID-10: Panid antigen detection for SAPS-CoV-2 by lateral flow assay: A national
923	139.	systematic evaluation of sensitivity and specificity for mass-testing. EClinical Medicine, 2021
024 025		36 : n 100021
925	1/10	Dickering S et al. Comparative performance of SARS-CoV-2 lateral flow antigen tests and
920	140.	association with detection of infectious virus in clinical specimens: a single-centre laboratory
928		evaluation study. Lancet Microbe. 2021 2 (9): n. F461-F471
929	141	Pilarowski G., et al., Performance characteristics of a ranid SARS-CoV-2 antiaen detection
930	± , ±.	assay at a public plaza testing site in San Francisco. The Journal of Infectious Diseases 2020
931		223 (7): p. 1139-1144.

932	142.	Pollock, N., et al., Performance and Implementation Evaluation of the Abbott BinaxNOW
933		Rapid Antigen Test in a High-throughput Drive-through Community Testing Site in
934		Massachusetts. Journal of Clinical Microbiology, 2021. 59(5): p. e00083-21.
935	143.	Pollock, N.R., et al., Performance and Operational Evaluation of the Access Bio CareStart
936		Rapid Antigen Test in a High-Throughput Drive-Through Community Testing Site in
937		Massachusetts. Open Forum Infectious Diseases, 2021. 8(7): p. ofab243.
938	144.	Porte, L., et al., Evaluation of two fluorescence immunoassays for the rapid detection of SARS-
939		CoV-2 antigen - new tool to detect infective COVID-19 patients. Peerl. 2020. 9 : p. e10801.
940	145.	Porte, L., et al., Evaluation of a novel antigen-based rapid detection test for the diagnosis of
941		SARS-CoV-2 in respiratory samples. International Journal of Infectious Diseases, 2020, 99 : p.
942		328-333
943	146.	Oahtani, M.A., et al., SARS-CoV-2 rapid antigen testing for departing passengers at
944		Vancouver international airport. Journal of Travel Medicine, 2021, taab085
945	147	Ristic M et al. Validation of the STANDARD O COVID-19 antigen test in Voivoding Serbig
946	,.	PLoS ONE. 2021. 16 (2): p. e0247606.
947	148.	Rottenstreich, A., et al., Rapid antiaen detection testing for universal screening for severe
948		acute respiratory syndrome coronavirus 2 in women admitted for delivery. American Journal
949		of Obstetrics and Gynecology, 2021, 224 (5): p. 539-540
950	149	Salvagno, G L., et al., Clinical assessment of the Roche SARS-CoV-2 ranid antigen test.
951	1.51	Diagnosis, 2021, 8 (3): p. 322-326.
952	150.	Sberna, G., et al., Letter of concern re: "Immunochromatographic test for the detection of
953		SARS-CoV-2 in saliva. J Infect Chemother. 2021 Feb:27(2):384-386. doi:
954		10.1016/i.iigc.2020.11.016.". Journal of Infection and Chemotherapy. 2021. 27 : p. 1129-
955		1130
956	151.	Schildgen, V., et al., Limits and opportunities of SARS-CoV-2 antigen rapid tests – an
957		experience hased perspective. Pathogens, 2020, 10 (1): p. 38
958	152.	Schuit, E., et al., Diagnostic accuracy of rapid antigen tests in asymptomatic and
959		presymptomatic close contacts of individuals with confirmed SARS-CoV-2 infection: cross
960		sectional study. British Medical Journal, 2021, 374 : p. n1676.
961	153.	Schwob, L-M., et al., <i>Diggnostic du Covid-19 en milieu ambulgtoire</i> . Revue médicale suisse.
962		2020. 17 (737): p. 862-865.
963	154.	Scohy, A., et al., Low performance of rapid antigen detection test as frontline testing for
964		<i>COVID-19 diagnosis</i> . Journal of Clinical Virology. 2020. 129 : p. 104455.
965	155.	Seitz, T., et al., Evaluation of rapid antigen tests based on saliva for the detection of SARS-
966		<i>CoV-2.</i> Journal of Medical Virology. 2021. 93 : p. 4161-4162.
967	156.	Sevnaeve. Y., et al., Evaluation of Two Rapid Antigenic Tests for the Detection of SARS-CoV-2
968		<i>in Nasopharvnaeal Swabs.</i> Journal of Clinical Medicine. 2021. 10 (13): p. 2774.
969	157.	Shah, M., et al., Performance of Repeat BinaxNOW SARS-CoV-2 Antigen Testing in a
970		<i>Community Setting, Wisconsin, November-December 2020, Clinical Infectious Diseases, 2021,</i>
971		73 : p. \$54–\$57.
972	158.	Shaikh, N., et al., Performance of a Rapid SARS-CoV-2 Antiaen Detection Assay in
973		Symptomatic Children. Pediatrics. 2021. 148 (3): p. e2021050832.
974	159.	Shaw, J.L.V., et al., Evaluation of the Abbott Panbio COVID-19 Ag rapid antigen test for the
975		detection of SARS-CoV-2 in asymptomatic Canadians. Diagnostic Microbiology and Infectious
976		Disease, 2021. 101 (4): p. 115514.
977	160.	Shidlovskava, E., et al., The Value of Rapid Antigen Tests to Identify Carriers of Viable SARS-
978		<i>CoV-2.</i> medRxiv [Preprint]; published March 12. 2021.
979	161.	Shrestha, B., et al., Sensitivity and specificity of lateral flow antiaen test kits for covid-19 in
980		asymptomatic population of guarantine centre of province 3. Kathmandu University Medical
981		Journal, 2020. 18 (2): p. 36-39.

982 983 984	162.	Smith, R.D., et al., Clinical Evaluation of Sofia Rapid Antigen Assay for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 among Emergency Department to Hospital Admissions Infection Control and Hospital Epidemiology 2021: p. 1-6
985	163	Sterbenc Δ et al. Usefulness of ranid antigen testing for SARS-CoV-2 screening of
986	105.	bealthcare workers, a nilot study. Clinical and Experimental Medicine, 2021; p. 1-4
987	164	Stohr et al. Self-testing for the detection of SARS-CoV-2 infection with ranid antigen tests
988	104.	for neonle with suspected COVID-19 in the community. Clinical Microbiology and Infection
989		
990	165	Stokes W et al. Clinical performance of the Abbott Paphio with pasopharypaeal throat
001	105.	and saliva swahs among symptomatic individuals with COVID-19. European Journal of Clinical
992		Microbiology & Infectious Diseases 2021 40 (8): n 1721-1726
992	166	Strömer A et al Performance of a Point-of-Care Test for the Ranid Detection of SARS-CoV-2
994	100.	Antigen Microorganisms 2020 9 (1)
995	167	Suzuki H et al Diagnostic performance of a novel digital immunoassay (RapidTesta SARS-
996	107.	CoV-2): a prospective observational study with 1 127 pasopharynaeal samples medRxiv
997		[Prenrint]: nublished August 04, 2021
998	168	Takeda Y M Mori and K Omi SARS-CoV-2 aRT-PCR Ct value distribution in Janan and
999	100.	nossible utility of ranid antigen testing kit, medRyiy [Prenrint]: nublished lune 19, 2020
1000	169	Takeuchi Y et al. The evolution of a newly developed antigen test ($OuickNavi^{m}$ -COVID19
1001	105.	Aa) for SARS-CoV-2: A prospective observational study in Japan Journal of Infection and
1002		Chemotherany 2021 27 (6): n 890-894
1003	170.	Takeuchi Y, et al., Diggnostic performance and characteristics of anterior nasal collection for
1004	1,01	the SARS-CoV-2 antiaen test: a prospective study. Scientific Reports 2021. 11 (1): p. 10519.
1005	171	Terpos, E. J. Ntanasis-Stathopoulos, and M. Skyarc, <i>Clinical Application of a New SARS-CoV-2</i>
1006	_/ _/	Antigen Detection Kit (Colloidal Gold) in the Detection of COVID-19. Diagnostics, 2021, 11 (6):
1007		p. 995.
1008	172.	Thakur, P., et al., Utility of Antigen-Based Rapid Diagnostic Test for Detection of SARS-CoV-2
1009		Virus in Routine Hospital Settings. Laboratory Medicine, 2021. Online ahead of print.
1010	173.	Thell, R., et al., Evaluation of a novel, rapid antigen detection test for the diagnosis of SARS-
1011		<i>CoV-2.</i> medRxiv [Preprint]; published April 22, 2021.
1012	174.	Thirion-Romero, I., et al., Evaluation of a rapid antigen test for SARS-CoV-2 in symptomatic
1013		patients and their contacts: a multicenter study. medRxiv [Preprint]; published May 24, 2021.
1014	175.	Tinker, S.C., et al., Point-of-Care Antigen Test for SARS-CoV-2 in Asymptomatic College
1015		Students. Emerging Infectious Diseases, 2021. 27(10).
1016	176.	Toptan, T., et al., Evaluation of a SARS-CoV-2 rapid antigen test: potential to help reduce
1017		community spread? Journal of Clinical Virology, 2020. 135: p. 104713.
1018	177.	Torres, I., et al., Point-of-care evaluation of a rapid antigen test (CLINITEST) Rapid COVID-19
1019		Antigen Test) for diagnosis of SARS-CoV-2 infection in symptomatic and asymptomatic
1020		individuals. Journal of Infection, 2021. 82(5): p. e11–e12.
1021	178.	Torres, I., et al., Real-life evaluation of a rapid antigen test (Panbio COVID-19 Ag Rapid Test
1022		Device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients.
1023		Clinical Microbiology and Infection, 2020. 27(4): p. 636.E1-636.E4.
1024	179.	Tsai, S.C., et al., Real world clinical performance of SARS-CoV-2 rapid antigen tests in
1025		suspected COVID-19 cases in Taiwan. Journal of the Formosan Medical Association, 2021.
1026		120 (10): p. 2042-2043.
1027	180.	Turcato, G., et al., Clinical application of a rapid antigen test for the detection of SARS-CoV-2
1028		infection in symptomatic and asymptomatic patients evaluated in the emergency
1029		department: a preliminary report. Journal of Infection, 2020. 82: p. E14-E16.
1030	181.	Van der Moeren, N., et al., Evaluation of the test accuracy of a SARS-CoV-2 rapid antigen test
1031		<i>in symptomatic community dwelling individuals in the Netherlands.</i> PLoS One, 2021. 16 (5): p.
1032		e0250886.

1033 1034 1025	182.	Van Honacker, E., et al., <i>Comparison of five SARS-CoV-2 rapid antigen detection tests in a hospital setting and performance of one antigen assay in routine practice: a useful tool to quide isolation processing lowers of Hospital Infection 2021</i> , 114 : p. 144, 152
1035 1036 1037 1038	183.	Villaverde, S., et al., <i>Diagnostic Accuracy of the Panbio SARS-CoV-2 Antigen Rapid Test</i> <i>Compared with Rt-Pcr Testing of Nasopharyngeal Samples in the Pediatric Population.</i> The lournal of Pediatrics 2021 232 : n P287-289 F4
1039 1040	184.	Weitzel, T., et al., <i>Comparative evaluation of four rapid SARS-CoV-2 antigen detection tests using universal transport medium</i> . Travel Medicine and Infectious Disease, 2020. 39 : p. 101042
1041		
1042 1043	185.	Weitzel, T., et al., SARS-CoV-2 rapid antigen detection tests. Lancet Infectious Diseases, 2021. 21 (8): p. 1067-1068.
1044	186.	Wertenauer, C., et al., Diggnostic Efficacy of Rapid Antigen Testing for SARS-CoV-2: The
1045		COVid-19 AntiGen (COVAG) study. medRxiv [Preprint]; published August 07, 2021.
1046	187.	Yin, N., et al., SARS-CoV-2 Diagnostic Tests: Algorithm and Field Evaluation From the Near
1047		Patient Testing to the Automated Diagnostic Platform. Frontiers in Medicine, 2021. 8: p. 380.
1048	188.	Young, B.C., D.W. Eyre, and K. Jeffery, Use of lateral flow devices allows rapid triage of
1049		patients with SARS-CoV-2 on admission to hospital. Journal of Infection, 2021. 82: p. 276-316.
1050	189.	Young, S., et al., Clinical evaluation of BD Veritor SARS-CoV-2 point-of-care test performance
1051		compared to PCR-based testing and versus the Sofia 2 SARS Antigen point-of-care test.
1052		Journal of Clinical Microbiology, 2020. 59 (1).
1053	190.	Foundation for Innovative New Diagnostics, FIND Evaluation of Bionote, Inc. NowCheck
1054		COVID-19 Ag Test. External Report Version 1.5, 20 April 2021, 2020.
1055	191.	Foundation for Innovative New Diagnostics, FIND Evaluation of RapiGEN Inc. BIOCREDIT
1056		COVID-19 Ag. External Report Version 2.1, 10 December, 2020.
1057	192.	Foundation for Innovative New Diagnostics, FIND Evaluation of SD Biosensor, Inc.
1058		STANDARD [™] F COVID-19 Ag FIA. External Report Version 2.1, 10 December, 2020.
1059	193.	Foundation for Innovative New Diagnostics, FIND Evaluation of SD Biosensor, Inc. STANDARD
1060		<i>Q COVID-19 Ag Test</i> . External Report Version 2.1, 10 December, 2020.
1061	194.	Foundation for Innovative New Diagnostics, FIND Evaluation of Boditech Medical, Inc.
1062		iChroma COVID-19 Ag Test. External Report Version 1.0, 23 February 2021, 2021.
1063	195.	Foundation for Innovative New Diagnostics, FIND Evaluation of Joysbio (Tianjin)
1064		Biotechnology Co., Lta. SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold). External Report
1065	100	Version 1.0, 11 February 2021, 2021.
1066	196.	Foundation for innovative New Diagnostics, FIND Evaluation of Guangznou Wonafo Biotecn
1067		Co., Lla Wonajo 2019-nCov Antigen Test (Lateral Flow Method). Public Report Version 1.0, 25
1008	107	February 2021, 2021.
1069	197.	Foundation for Innovative New Diagnostics, FIND Evaluation of Abbott Panbio COVID-19 Ag
1070	100	Rupiu Test Device (NASAL). External Report Version 1.0, 11 February 2021, 2021.
1071	190.	COVID 10 Ag Tect, paged swab. External Papert Version 1.0, 20 March 2021, 2021
1072	100	COVID-19 Ay rest, husur swub. External Report Version 1.0, 50 March 2021, 2021.
1073	199.	CoV-2 External Report Version 1.0. 29 March 2021, 2021
1074	200	Equipation for Innovative New Diagnostics. FIND Evaluation of Mologic Ltd. COVID 19 RADID
1075	200.	ANTIGEN TEST External Report Version 1.0. 23 April 2021, 2021
1077	201	Foundation for Innovative New Diagnostics FIND Evaluation of NADAL COVID-19 Ag Rapid
1078	201.	Test External Report Version 1.0. 26 April 2021, 2021
1079	202	Foundation for Innovative New Diagnostics FIND Evaluation of Acon Biotech (Hanazhou) Co
1080	-92.	Itd: Flowflex SARS-CoV-2 Antigen Ranid Test. External Report Version 1.0.9 June 2021, 2021
1081	203	Foundation for Innovative New Diagnostics. FIND Evaluation of Edinburgh Genetics:
1082	200.	ActivXpress+ COVID-19 Antigen Complete Testing Kit. External Report Version 1.0. 26 April
1083		2021, 2021.

1084	204.	Foundation for Innovative New Diagnostics, FIND Evaluation of Green Cross Medical Sciences
1085		Corp.; Genedia W COVID-19 Ag. External Report Version 1.0, 25 April 2021, 2021.
1086	205.	Foundation for Innovative New Diagnostics, FIND Evaluation of Hotgen; Novel Coronavirus
1087		2019-nCoV Antigen Test (Colloidal Gold). External Report Version 2.0, [15 September 2021],
1088		2021.
1089	206.	Foundation for Innovative New Diagnostics, FIND Evaluation of Abbott; Panbio COVID-19 Ag
1090		Rapid Test Device. Country Specific External Report Version 1.0, 28 April 2021, 2021.
1091	207.	Foundation for Innovative New Diagnostics, FIND Evaluation of Premier Medical Corporation
1092		Pvt. Ltd; Sure Status COVID-19 Antigen Card Test. External Report Version 1.1, 18 August
1093		2021, 2021.
1094	208.	Foundation for Innovative New Diagnostics, FIND Evaluation of SD Bionsensor, Inc.;
1095		STANDARD Q COVID-19 Ag Test. External Report (Continue from V2.1) Version 1, 22 April
1096		2021, 2021.
1097	209.	Foundation for Innovative New Diagnostics, FIND Evaluation of SD Biosensor, Inc.; STANDARD
1098		Q COVID-19 Ag Test, nasal swab. External Report Version 2.0, 12 April 2021, 2021.
1099	210.	Page, M.J., et al., The PRISMA 2020 statement: an updated guideline for reporting systematic
1100		reviews. British Medical Journal, 2021. 372 : p. n71.
1101	211.	Lindner, A., et al., SARS-CoV-2 patient self-testing with an antigen-detecting rapid test: a
1102		head-to-head comparison with professional testing. medRxiv [Preprint]; published January
1103		08, 2021.
1104	212.	Deerain, J., et al., Assessment of the analytical sensitivity of ten lateral flow devices against
1105		the SARS-CoV-2 omicron variant. J Clin Microbiol, 2021: p. jcm0247921.
1106	213.	Bekliz, M., et al., Analytical sensitivity of seven SARS-CoV-2 antigen-detecting rapid tests for
1107		<i>Omicron variant.</i> medRxiv [Preprint]; published December 22, 2021.
1108	214.	Kissler, S.M., et al., Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated
1109		Persons. N Engl J Med, 2021. 385 (26): p. 2489-2491.
1110	215.	Hay, J.A., et al., Viral dynamics and duration of PCR positivity of the SARS-CoV-2 Omicron
1111		variant. medRxiv [Preprint]; published January 14, 2022.
1112	216.	Adamson, B., et al., Discordant SARS-CoV-2 PCR and Rapid Antigen Test Results When
1113		Infectious: A December 2021 Occupational Case Series. medRxiv [Preprint]; published January
1114		05, 2022.
1115	217.	Marais, G., et al., Saliva swabs are the preferred sample for Omicron detection. medRxiv
1116		[Preprint]; published December 24, 2021.
1117	218.	Schrom, J., et al., Direct Comparison of SARS CoV-2 Nasal RT- PCR and Rapid Antigen Test
1118		(BinaxNOW(TM)) at a Community Testing Site During an Omicron Surge. medRxiv [Preprint];
1119		published January 12, 2022.
1120	219.	Audigé, A., et al., Reduced Relative Sensitivity of the Elecsys SARS-CoV-2 Antigen Assay in
1121		Saliva Compared to Nasopharyngeal Swabs. Microorganisms, 2021. 9(8): p. 1700.
1122	220.	Dye, C., et al., Data sharing in public health emergencies: a call to researchers. Bull World
1123		Health Organ, 2016. 94 (3): p. 158.
1124	221.	Modjarrad, K., et al., Developing Global Norms for Sharing Data and Results during Public
1125		Health Emergencies. PLoS Med, 2016. 13 (1): p. e1001935.
1126	222.	Mina, M.J., R. Parker, and D.B. Larremore, <i>Rethinking Covid-19 Test Sensitivity - A Strategy for</i>
1127		Containment. New England Journal of Medicine, 2020. 383 (22).